Cover Page - shares	9 Months Ended
Cover Page - shares	Sep. 30, 2019	Oct. 29, 2019
Cover page.
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2019
Document Transition Report	false
Entity File Number	001-36326
Entity Registrant Name	Endo International plc
Entity Incorporation, State or Country Code	L2
Entity Tax Identification Number	68-0683755
Entity Address, Address Line One	First Floor, Minerva House, Simmonscourt Road
Entity Address, City or Town	Ballsbridge, Dublin 4,
Entity Address, Country	IE
Entity Address, Postal Zip Code	Not Applicable
City Area Code	353
Local Phone Number	1-268-2000
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Title of 12(b) Security	Ordinary shares, nominal value $0.0001 per share
Trading Symbol	ENDP
Security Exchange Name	NASDAQ
Entity Ordinary Shares Outstanding (in shares)		226,776,161
Amendment Flag	false
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Entity Central Index Key	0001593034
Current Fiscal Year End Date	--12-31

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
CURRENT ASSETS:
Cash and cash equivalents	$ 1,526,250	$ 1,149,113
Restricted cash and cash equivalents	222,491	305,368
Accounts receivable, net	420,195	470,570
Inventories, net	338,513	322,179
Prepaid expenses and other current assets	105,349	56,139
Income taxes receivable	36,337	39,781
Total current assets	2,649,135	2,343,150
PROPERTY, PLANT AND EQUIPMENT, NET	501,352	498,892
OPERATING LEASE ASSETS	53,839	0
GOODWILL	3,615,322	3,764,636
OTHER INTANGIBLES, NET	2,938,217	3,457,306
DEFERRED INCOME TAXES	0	678
OTHER ASSETS	77,001	67,731
TOTAL ASSETS	9,834,866	10,132,393
CURRENT LIABILITIES:
Accounts payable and accrued expenses	937,181	1,009,200
Current portion of legal settlement accrual	674,943	905,085
Current portion of operating lease liabilities	10,575	0
Current portion of long-term debt	34,150	34,150
Income taxes payable	10,878	1,661
Total current liabilities	1,667,727	1,950,096
DEFERRED INCOME TAXES	32,105	34,487
LONG-TERM DEBT, LESS CURRENT PORTION, NET	8,364,911	8,224,269
LONG-TERM LEGAL SETTLEMENT ACCRUAL, LESS CURRENT PORTION	9,113	0
OPERATING LEASE LIABILITIES, LESS CURRENT PORTION	50,965	0
OTHER LIABILITIES	371,522	421,824
COMMITMENTS AND CONTINGENCIES (NOTE 13)
SHAREHOLDERS' DEFICIT:
Euro deferred shares, $0.01 par value; 4,000,000 shares authorized and issued at both September 30, 2019 and December 31, 2018	44	46
Ordinary shares, $0.0001 par value; 1,000,000,000 shares authorized; 226,763,072 and 224,382,791 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively	23	22
Additional paid-in capital	8,894,646	8,855,810
Accumulated deficit	(9,333,571)	(9,124,932)
Accumulated other comprehensive loss	(222,619)	(229,229)
Total equity	(661,477)	(498,283)
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT	$ 9,834,866	$ 10,132,393

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares	Sep. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Euro deferred shares, par value (in dollars per share)	$ 0.01	$ 0.01
Euro deferred shares, shares authorized (in shares)	4,000,000	4,000,000
Euro deferred shares, shares issued (in shares)	4,000,000	4,000,000
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	1,000,000,000	1,000,000,000
Common stock, shares issued (in shares)	226,763,072	224,382,791
Common stock, shares outstanding (in shares)	226,763,072	224,382,791

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Statement [Abstract]
TOTAL REVENUES, NET	$ 729,426	$ 745,466	$ 2,149,564	$ 2,160,689
COSTS AND EXPENSES:
Cost of revenues	389,165	412,965	1,169,282	1,198,468
Selling, general and administrative	168,329	163,791	471,749	478,615
Research and development	36,519	39,683	96,353	160,431
Litigation-related and other contingencies, net	(14,414)	(1,750)	(4,093)	15,370
Asset impairment charges	4,766	142,217	258,652	613,400
Acquisition-related and integration items	16,025	1,288	(26,983)	13,284
Interest expense, net	136,903	131,847	404,387	385,896
Gain on extinguishment of debt	0	0	(119,828)	0
Other expense (income), net	16,203	(1,507)	20,408	(33,216)
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAX	(24,070)	(143,068)	(120,363)	(671,559)
INCOME TAX EXPENSE	17,361	3,003	31,732	24,729
LOSS FROM CONTINUING OPERATIONS	(41,431)	(146,071)	(152,095)	(696,288)
DISCONTINUED OPERATIONS, NET OF TAX (NOTE 3)	(37,984)	(27,134)	(51,898)	(43,273)
NET LOSS	$ (79,415)	$ (173,205)	$ (203,993)	$ (739,561)
NET LOSS PER SHARE—BASIC:
Continuing operations (in dollars per share)	$ (0.18)	$ (0.65)	$ (0.67)	$ (3.11)
Discontinued operations (in dollars per share)	(0.17)	(0.12)	(0.23)	(0.19)
Basic (in dollars per share)	(0.35)	(0.77)	(0.90)	(3.30)
NET LOSS PER SHARE—DILUTED:
Continuing operations (in dollars per share)	(0.18)	(0.65)	(0.67)	(3.11)
Discontinued operations (in dollars per share)	(0.17)	(0.12)	(0.23)	(0.19)
Diluted (in dollars per share)	$ (0.35)	$ (0.77)	$ (0.90)	$ (3.30)
WEIGHTED AVERAGE SHARES:
Basic (in shares)	226,598	224,132	225,804	223,829
Diluted (in shares)	226,598	224,132	225,804	223,829

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Statement of Comprehensive Income [Abstract]
Net loss	$ (79,415)	$ (173,205)	$ (203,993)	$ (739,561)
Net unrealized (loss) gain on foreign currency:
Foreign currency translation (loss) gain arising during the period	(2,515)	4,735	6,610	(7,033)
Less: reclassification adjustments for (gain) loss realized in net loss	0	0	0	0
Foreign currency translation gain (loss)	(2,515)	4,735	6,610	(7,033)
OTHER COMPREHENSIVE (LOSS) INCOME	(2,515)	4,735	6,610	(7,033)
COMPREHENSIVE LOSS	$ (81,930)	$ (168,470)	$ (197,383)	$ (746,594)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
OPERATING ACTIVITIES:
Net loss	$ (203,993)	$ (739,561)
Adjustments to reconcile Net loss to Net cash provided by operating activities:
Depreciation and amortization	468,409	556,503
Inventory step-up	0	261
Share-based compensation	48,909	43,722
Amortization of debt issuance costs and discount	13,799	15,289
Deferred income taxes	(2,452)	13,118
Change in fair value of contingent consideration	(26,983)	11,731
Gain on extinguishment of debt	(119,828)	0
Asset impairment charges	258,652	613,400
Gain on sale of business and other assets	(3,101)	(29,859)
Changes in assets and liabilities which provided (used) cash:
Accounts receivable	58,630	31,634
Inventories	(32,761)	52,499
Prepaid and other assets	15,577	993
Accounts payable, accrued expenses and other liabilities	(378,547)	(367,979)
Income taxes payable/receivable	22,933	(4,759)
Net cash provided by operating activities	119,244	196,992
INVESTING ACTIVITIES:
Purchases of property, plant and equipment, excluding capitalized interest	(47,812)	(56,544)
Capitalized interest payments	(3,207)	(2,569)
Proceeds from sale of business and other assets, net	4,780	43,753
Other investing activities	912	1,678
Net cash used in investing activities	(45,327)	(13,682)
FINANCING ACTIVITIES:
Proceeds from issuance of notes, net	1,483,125	0
Repayments of notes	(1,501,788)	0
Repayments of term loans	(25,614)	(25,614)
Proceeds from draw of revolving debt	300,000	0
Repayments of other indebtedness	(7,826)	(3,921)
Payments for debt issuance and extinguishment costs	(6,414)	0
Payments for contingent consideration	(11,846)	(28,664)
Payments of tax withholding for restricted shares	(10,077)	(5,082)
Proceeds from exercise of options	4	473
Net cash provided by (used in) financing activities	219,564	(62,808)
Effect of foreign exchange rate	780	(608)
NET INCREASE IN CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS	294,261	119,894
CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, BEGINNING OF PERIOD	1,476,837	1,311,014
CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, END OF PERIOD	1,771,098	1,430,908
SUPPLEMENTAL INFORMATION:
Cash paid into Qualified Settlement Funds for mesh legal settlements	185,745	216,770
Cash paid out of Qualified Settlement Funds for mesh legal settlements	266,958	248,485
Other cash distributions for mesh legal settlements	$ 13,334	$ 17,114

Basis of Presentation	9 Months Ended
Basis of Presentation	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	NOTE 1. BASIS OF PRESENTATION Endo International plc is an Ireland-domiciled, global specialty pharmaceutical company focused on generic and branded pharmaceuticals. We aim to be the premier partner to healthcare professionals and payment providers, delivering an innovative suite of generic and branded drugs to meet patients’ needs. Unless otherwise indicated or required by the context, references throughout to “Endo,” the “Company,” “we,” “our” or “us” refer to financial information and transactions of Endo International plc and its subsidiaries. The accompanying unaudited Condensed Consolidated Financial Statements of Endo International plc and its subsidiaries have been prepared in accordance with United States (U.S.) generally accepted accounting principles (U.S. GAAP) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying Condensed Consolidated Financial Statements of Endo International plc and its subsidiaries, which are unaudited, include all normal and recurring adjustments necessary for a fair statement of the Company’s financial position as of September 30, 2019 and the results of its operations and its cash flows for the periods presented. Operating results for the three and nine months ended September 30, 2019 are not necessarily indicative of the results that may be expected for the year ending December 31, 2019. The year-end Condensed Consolidated Balance Sheet data as of December 31, 2018 was derived from audited financial statements but does not include all disclosures required by U.S. GAAP. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our Consolidated Financial Statements and accompanying notes included in the Annual Report. Certain prior period amounts have been reclassified to conform to the current period presentation.

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Significant Accounting Policies Added or Updated since December 31, 2018

Significant changes to our significant accounting policies since December 31, 2018 are detailed below. For additional discussion of the Company’s significant accounting policies, see Note 2. Summary of Significant Accounting Policies in the Consolidated Financial Statements, included in Part IV, Item 15 of the Annual Report.

Lease Accounting. The Company adopted Accounting Standards Codification Topic 842, Leases (ASC 842) on January 1, 2019. For further discussion of the adoption, refer to the “Recent Accounting Pronouncements Adopted or Otherwise Effective as of September 30, 2019” section below. ASC 842 applies to a number of arrangements to which the Company is party.

Whenever the Company enters into a new arrangement, it must determine, at the inception date, whether the arrangement is or contains a lease. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset.

If a lease exists, the Company must then determine the separate lease and nonlease components of the arrangement. Each right to use an underlying asset conveyed by a lease arrangement should generally be considered a separate lease component if it both: (i) can benefit the Company without depending on other resources not readily available to the Company and (ii) does not significantly affect and is not significantly affected by other rights of use conveyed by the lease. Aspects of a lease arrangement that transfer other goods or services to the Company but do not meet the definition of lease components are considered nonlease components. The consideration owed by the Company pursuant to a lease arrangement is generally allocated to each lease and nonlease components for accounting purposes. However, the Company has elected, for all of its leases, to not separate lease and nonlease components. Each lease component is accounted for separately from other lease components, but together with the associated nonlease components.

For each lease, the Company must then determine the lease term, the present value of lease payments and the classification of the lease as either an operating or finance lease.

The lease term is the period of the lease not cancellable by the Company, together with periods covered by: (i) renewal options the Company is reasonably certain to exercise, (ii) termination options the Company is reasonably certain not to exercise and (iii) renewal or termination options that are controlled by the lessor.

The present value of lease payments is calculated based on:

•

Lease payments—Lease payments include fixed and certain variable payments, less lease incentives, together with amounts probable of being owed by the Company under residual value guarantees and, if reasonably certain of being paid, the cost of certain renewal options and early termination penalties set forth in the lease arrangement. Lease payments exclude consideration that is not related to the transfer of goods and services to the Company.

•

Discount rate—The discount rate must be determined based on information available to the Company upon the commencement of a lease. Lessees are required to use the rate implicit in the lease whenever such rate is readily available; however, as the implicit rate in the Company’s leases is generally not readily determinable, the Company generally uses the hypothetical incremental borrowing rate it would have to pay to borrow an amount equal to the lease payments, on a collateralized basis, over a timeframe similar to the lease term.

In making the determination of whether a lease is an operating lease or a finance lease, the Company considers the lease term in relation to the economic life of the leased asset, the present value of lease payments in relation to the fair value of the leased asset and certain other factors, including the lessee's and lessor's rights, obligations and economic incentives over the term of the lease.

Generally, upon the commencement of a lease, the Company will record a lease liability and a right-of-use (ROU) asset. However, the Company has elected, for all underlying assets with initial lease terms of twelve months or less (known as short-term leases), to not recognize a lease liability or ROU asset. Lease liabilities are initially recorded at lease commencement as the present value of future lease payments. ROU assets are initially recorded at lease commencement as the initial amount of the lease liability, together with the following, if applicable: (i) initial direct costs incurred by the lessee and (ii) lease payments made by the lessor, net of lease incentives received, prior to lease commencement.

Over the lease term, the Company generally increases its lease liabilities using the effective interest method and decreases its lease liabilities for lease payments made. The Company generally amortizes its ROU assets over the shorter of the estimated useful life and the lease term and assesses its ROU assets for impairment, similar to other long-lived assets.

For finance leases, amortization expense and interest expense are recognized separately in the Condensed Consolidated Statements of Operations, with amortization expense generally recorded on a straight-line basis and interest expense recorded using the effective interest method. For operating leases, a single lease cost is generally recognized in the Condensed Consolidated Statements of Operations on a straight-line basis over the lease term unless an impairment has been recorded with respect to a leased asset. Lease costs for short-term leases not recognized in the Condensed Consolidated Balance Sheets are recognized in the Condensed Consolidated Statements of Operations on a straight-line basis over the lease term. Variable lease costs not initially included in the lease liability and ROU asset impairment charges are expensed as incurred.

Cloud Computing Arrangements. The Company may from time to time incur costs in connection with hosting arrangements that are service contracts. Subsequent to the Company’s January 1, 2019 adoption of Accounting Standards Update (ASU) No. 2018-15, “Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract” (ASU 2018-15), which is further described below, the Company capitalizes any such implementation costs, expenses them over the terms of the respective hosting arrangements and subjects them to impairment testing consistent with other long-lived assets.

Recent Accounting Pronouncements

Recently Issued Accounting Pronouncements Not Yet Adopted as of September 30, 2019

In August 2018, the Financial Accounting Standards Board (FASB) issued ASU No. 2018-13, “Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement” (ASU 2018-13). ASU 2018-13 modifies the disclosure requirements on fair value measurements in Accounting Standards Codification Topic 820, Fair Value Measurement. ASU 2018-13 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Certain aspects of ASU 2018-13 require prospective treatment, while others require retrospective treatment. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2018-13 on the Company’s disclosures.

In November 2018, the FASB issued ASU No. 2018-18, “Clarifying the Interaction Between Topic 808 and Topic 606” (ASU 2018-18). The main provisions of ASU 2018-18 include: (i) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue when the collaborative arrangement participant is a customer in the context of a unit of account and (ii) precluding the presentation of transactions with collaborative arrangement participants that are not directly related to sales to third parties together with revenue. ASU 2018-18 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. ASU 2018-18 should be applied retrospectively to the date of initial application of Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (ASC 606), which was January 1, 2018 for the Company. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2018-18 on the Company’s consolidated results of operations, financial position and disclosures.

Recent Accounting Pronouncements Adopted or Otherwise Effective as of September 30, 2019

In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)” (ASU 2016-02) to establish a comprehensive new accounting standard for leases. ASU 2016-02, together with a series of subsequently-issued related ASUs, has been codified in ASC 842. ASC 842 supersedes the lease accounting requirements in Accounting Standards Codification Topic 840, Leases (ASC 840), and requires lessees to, among other things, recognize on the balance sheet a right-of-use asset and a right-of-use lease liability, representing the present value of future minimum lease payments, for most leases.

The Company adopted ASC 842 using the modified retrospective approach with an effective date of January 1, 2019 for leases that existed on that date. Prior period results continue to be presented under ASC 840 based on the accounting standards originally in effect for such periods.

The Company has elected certain practical expedients permitted under the transition guidance within ASC 842 to leases that commenced before January 1, 2019, including the package of practical expedients, as well as the practical expedient permitting the Company to not assess whether certain land easements contain leases. Due to the Company's election of these practical expedients, the Company has carried forward certain historical conclusions for existing contracts, including conclusions relating to initial direct costs and to the existence and classification of leases.

On January 1, 2019, as a result of adopting ASC 842, the Company recognized new ROU assets, current lease liabilities and noncurrent lease liabilities associated with operating leases of $59.4 million, $11.0 million and $57.3 million, respectively, which were recorded in the Condensed Consolidated Balance Sheets as Operating lease assets, Current portion of operating lease liabilities and Operating lease liabilities, less current portion, respectively. The Company also derecognized certain assets and liabilities related to existing build-to-suit lease arrangements for which construction was completed prior to the date of transition and recognized new finance lease ROU assets and lease liabilities related to those lease arrangements. The net effect of the Company’s adoption of ASC 842 resulted in a net increase to Accumulated deficit of $4.6 million.

In August 2018, the FASB issued ASU 2018-15. ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (including hosting arrangements where a software license is deemed to exist). ASU 2018-15 also requires the customer to expense any such capitalized implementation costs over the term of the hosting arrangement and to apply the existing impairment guidance for long-lived assets to such capitalized costs. Additionally, ASU 2018-15 sets forth required disclosures and guidance on financial statement classification for expenses, cash flows and balances related to implementation costs within the scope of ASU 2018-15. The Company early adopted this guidance during the first quarter of 2019 on a prospective basis.

Restructuring

9 Months Ended

Sep. 30, 2019

Restructuring and Related Activities [Abstract]

RESTRUCTURING

NOTE 4. RESTRUCTURING

Set forth below are disclosures relating to restructuring initiatives that resulted in material expenses or cash expenditures during any of the three- or nine-month periods ended September 30, 2019 or 2018 or had material restructuring liabilities at either September 30, 2019 or December 31, 2018. Employee separation, retention and certain other employee benefit-related costs related to our restructurings are expensed ratably over the requisite service period. Other restructuring costs are generally expensed as incurred.

2017 Generic Pharmaceuticals Restructuring Initiative

On July 21, 2017, the Company announced that after completing a comprehensive review of its manufacturing network, it would be ceasing operations and closing its manufacturing and distribution facilities in Huntsville, Alabama (the 2017 Generic Pharmaceuticals Restructuring Initiative). The closure of the facilities was completed in June 2018 and the facilities were sold in the fourth quarter of 2018 for net cash proceeds of $23.1 million, resulting in a net gain on disposal of $12.5 million.

As a result of the 2017 Generic Pharmaceuticals Restructuring Initiative, the Company incurred pre-tax charges of $4.8 million and $59.6 million during the three and nine months ended September 30, 2018, respectively. During the three months ended September 30, 2018, the expenses consisted of employee separation, retention and other benefit-related costs of $2.1 million and certain other charges of $2.7 million. During the nine months ended September 30, 2018, the expenses consisted of charges relating to accelerated depreciation of $35.2 million, employee separation, retention and other benefit-related costs of $9.8 million, asset impairment charges of $2.6 million and certain other charges of $12.0 million. These charges are included in the Generic Pharmaceuticals segment. Accelerated depreciation and employee separation, retention and other benefit-related costs are primarily included in Cost of revenues in the Condensed Consolidated Statements of Operations. Certain other charges are included in both Cost of revenues and Selling, general and administrative expenses in the Condensed Consolidated Statements of Operations.

The Company did not incur any material pre-tax charges as a result of the 2017 Generic Pharmaceuticals Restructuring Initiative during the three and nine months ended September 30, 2019 and does not expect to incur additional material pre-tax restructuring-related expenses related to this initiative.

The liability related to the 2017 Generic Pharmaceuticals Restructuring Initiative is primarily included in Accounts payable and accrued expenses in the Condensed Consolidated Balance Sheets. Changes to this liability during the nine months ended September 30, 2019 were as follows (in thousands):



	Employee Separation and Other Benefit-Related Costs			Other Restructuring Costs			Total
Liability balance as of January 1, 2019	$	4,239		$	48		$	4,287
Cash distributions	(4,239		)	(48		)	(4,287		)
Liability balance as of September 30, 2019	$	—		$	—		$	—

January 2018 Restructuring Initiative

In January 2018, the Company initiated a restructuring initiative that included a reorganization of its Generic Pharmaceuticals segment’s research and development network, a further simplification of the Company’s manufacturing networks and a company-wide unification of certain corporate functions (the January 2018 Restructuring Initiative). As a result of the January 2018 Restructuring Initiative, the Company incurred pre-tax charges of $23.8 million during the nine months ended September 30, 2018. The expenses primarily consisted of employee separation, retention and other benefit-related costs of $22.1 million and certain other charges of $1.7 million. Of the total charges incurred, $10.8 million are included in the Generic Pharmaceuticals segment, $5.2 million are included in Corporate unallocated costs, $4.0 million are included in the Sterile Injectables segment, $3.1 million are included in the International Pharmaceuticals segment and $0.7 million are included in the Branded Pharmaceuticals segment. Employee separation, retention and other benefit-related costs are included in Cost of revenues, Selling, general and administrative and Research and development expenses in the Condensed Consolidated Statements of Operations. Certain other charges are primarily included in Selling, general and administrative expenses in the Condensed Consolidated Statements of Operations.

The Company did not incur any material pre-tax charges as a result of the January 2018 Restructuring Initiative during any of the other periods presented and does not expect to incur additional material pre-tax restructuring-related expenses related to this initiative. At December 31, 2018, the remaining liability balance was $1.1 million. Substantially all related cash payments were made by the end of the first quarter of 2019.

Segment Results

9 Months Ended

Sep. 30, 2019

Segment Reporting [Abstract]

SEGMENT RESULTS

NOTE 5. SEGMENT RESULTS

During the first quarter of 2019, the Company changed the names of its reportable segments. This change, which was intended to simplify the segments’ names, had no impact on the Company’s unaudited Condensed Consolidated Financial Statements or segment results for any of the periods presented. The Company’s four reportable business segments are set forth below. These segments reflect the level at which the chief operating decision maker regularly reviews financial information to assess performance and to make decisions about resources to be allocated. Each segment derives revenue from the sales or licensing of its respective products and is discussed in more detail below.

We evaluate segment performance based on each segment’s adjusted income from continuing operations before income tax, which we define as Loss from continuing operations before income tax and before certain upfront and milestone payments to partners; acquisition-related and integration items, including transaction costs and changes in the fair value of contingent consideration; cost reduction and integration-related initiatives such as separation benefits, retention payments, other exit costs and certain costs associated with integrating an acquired company’s operations; asset impairment charges; amortization of intangible assets; inventory step-up recorded as part of our acquisitions; litigation-related and other contingent matters; gains or losses from early termination of debt; gains or losses from the sales of businesses and other assets; foreign currency gains or losses on intercompany financing arrangements; and certain other items.

Certain of the corporate expenses incurred by the Company are not directly attributable to any specific segment. Accordingly, these costs are not allocated to any of the Company’s segments and are included in the results below as “Corporate unallocated costs.” Interest income and expense are also considered corporate items and not allocated to any of the Company’s segments. The Company’s consolidated adjusted income from continuing operations before income tax is equal to the combined results of each of its segments less these unallocated corporate items.

Branded Pharmaceuticals

Our Branded Pharmaceuticals segment includes a variety of branded prescription products to treat and manage conditions in urology, urologic oncology, endocrinology, pain and orthopedics. The products in this segment include XIAFLEX^®, SUPPRELIN^®LA, NASCOBAL^® Nasal Spray, AVEED^®, PERCOCET^®, TESTOPEL^®, LIDODERM^®, VOLTAREN^®Gel, EDEX^®, FORTESTA^®Gel and TESTIM^®, among others.

Sterile Injectables

Our Sterile Injectables segment consists primarily of branded sterile injectable products such as VASOSTRICT^®, ADRENALIN^® and APLISOL^®, among others, and certain generic sterile injectable products, including ertapenem for injection, the authorized generic of Merck Sharp & Dohme Corp’s Invanz^®, and ephedrine sulfate injection, among others.

Generic Pharmaceuticals

Our Generic Pharmaceuticals segment consists of a differentiated product portfolio including solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmics and sprays and includes products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women’s health and cardiovascular disease markets, among others.

International Pharmaceuticals

Our International Pharmaceuticals segment includes a variety of specialty pharmaceutical products sold outside the U.S., primarily in Canada through our operating company Paladin Labs Inc. (Paladin). This segment’s key products serve growing therapeutic areas, including attention deficit hyperactivity disorder, pain, women’s health and oncology.

The following represents selected information for the Company’s reportable segments for the three and nine months ended September 30, 2019 and 2018 (in thousands):



	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Net revenues from external customers:
Branded Pharmaceuticals	$	217,313	$	220,100	$	629,851	$	632,972
Sterile Injectables	263,635		237,150		777,963		670,847
Generic Pharmaceuticals	218,012		257,969		654,322		748,445
International Pharmaceuticals (1)	30,466		30,247		87,428		108,425
Total net revenues from external customers	$	729,426	$	745,466	$	2,149,564	$	2,160,689
Adjusted income from continuing operations before income tax:
Branded Pharmaceuticals	$	91,444	$	84,891	$	253,417	$	262,454
Sterile Injectables	197,974		170,329		566,345		513,082
Generic Pharmaceuticals	29,433		82,555		128,738		247,137
International Pharmaceuticals	11,511		13,377		35,053		45,594
Total segment adjusted income from continuing operations before income tax	$	330,362	$	351,152	$	983,553	$	1,068,267

__________


(1)	Revenues generated by our International Pharmaceuticals segment are primarily attributable to external customers located in Canada.

There were no material revenues from external customers attributed to an individual country outside of the U.S. during any of the periods presented. There were no material tangible long-lived assets in an individual country other than the U.S. as of September 30, 2019 or December 31, 2018.

The table below provides reconciliations of our Total consolidated loss from continuing operations before income tax, which is determined in accordance with U.S. GAAP, to our total segment adjusted income from continuing operations before income tax for the three and nine months ended September 30, 2019 and 2018 (in thousands):



	Three Months Ended September 30,						Nine Months Ended September 30,
	2019			2018			2019			2018
Total consolidated loss from continuing operations before income tax	$	(24,070	)	$	(143,068	)	$	(120,363	)	$	(671,559	)
Interest expense, net	136,903			131,847			404,387			385,896
Corporate unallocated costs (1)	37,891			49,187			124,351			144,693
Amortization of intangible assets	131,932			161,275			417,949			471,662
Inventory step-up	—			71			—			261
Upfront and milestone payments to partners	1,672			4,731			4,055			43,027
Retention and separation benefits and other cost reduction initiatives (2)	11,023			4,001			15,172			82,141
Certain litigation-related and other contingencies, net (3)	(14,414		)	(1,750		)	(4,093		)	15,370
Asset impairment charges (4)	4,766			142,217			258,652			613,400
Acquisition-related and integration items (5)	16,025			1,288			(26,983		)	13,284
Gain on extinguishment of debt	—			—			(119,828		)	—
Foreign currency impact related to the remeasurement of intercompany debt instruments	(922		)	1,528			2,874			(1,560		)
Other, net (6)	29,556			(175		)	27,380			(28,348		)
Total segment adjusted income from continuing operations before income tax	$	330,362		$	351,152		$	983,553		$	1,068,267

__________


(1)	Amounts include certain corporate overhead costs, such as headcount, facility and corporate litigation expenses and certain other income and expenses.

(2)

Amounts for both the three and nine months ended September 30, 2019 include $6.7 million of costs associated with retention bonuses awarded to certain senior management of the Company. Other amounts during each of the periods presented related primarily to our restructuring initiatives. Such amounts included employee separation costs of $2.2 million during the nine months ended September 30, 2019 and other charges of $4.4 million and $6.3 million during the three and nine months ended September 30, 2019, respectively. During the three and nine months ended September 30, 2018, such amounts included employee separation costs of $2.1 million and $32.7 million, respectively, charges to increase excess inventory reserves of $0.2 million and $2.8 million, respectively, and other charges of $1.7 million and $11.4 million, respectively. Also included in the amount for the nine months ended September 30, 2018 is accelerated depreciation of $35.2 million. See Note 4. Restructuring for discussion of our material restructuring initiatives.


(3)	Amounts include adjustments to our accruals for litigation-related settlement charges and certain settlement proceeds related to suits filed by our subsidiaries. Our material legal proceedings and other contingent matters are described in more detail in Note 13. Commitments and Contingencies.


(4)	Amounts primarily relate to charges to impair goodwill and intangible assets as further described in Note 9. Goodwill and Other Intangibles.


(5)	Amounts primarily relate to changes in the fair value of contingent consideration.

(6)

Amounts during the three and nine months ended September 30, 2019 include $17.5 million for contract termination costs incurred as a result of certain product discontinuation activities in our International Pharmaceuticals segment and $14.1 million for a premium associated with an extended reporting period endorsement on an expiring insurance program. The remaining amounts primarily relate to gains on sales of businesses and other assets.

Asset information is not reviewed or included within our internal management reporting. Therefore, the Company has not disclosed asset information for each reportable segment.

The Company disaggregates its revenue from contracts with customers into the categories included in the table below (in thousands). The Company believes these categories depict how the nature, timing and uncertainty of revenue and cash flows are affected by economic factors.



	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Branded Pharmaceuticals:
Specialty Products:
XIAFLEX®	$	82,756	$	64,214	$	226,118	$	184,855
SUPPRELIN® LA	20,772		20,408		66,542		60,948
Other Specialty (1)	28,470		27,614		78,397		69,226
Total Specialty Products	$	131,998	$	112,236	$	371,057	$	315,029
Established Products:
PERCOCET®	$	28,561	$	30,730	$	88,199	$	93,539
TESTOPEL®	13,236		15,962		40,830		44,976
Other Established (2)	43,518		61,172		129,765		179,428
Total Established Products	$	85,315	$	107,864	$	258,794	$	317,943
Total Branded Pharmaceuticals (3)	$	217,313	$	220,100	$	629,851	$	632,972
Sterile Injectables:
VASOSTRICT®	$	129,691	$	112,333	$	384,854	$	332,387
ADRENALIN®	40,311		35,460		133,468		101,858
APLISOL®	28,085		15,992		55,996		49,064
Ertapenem for injection	21,853		25,798		79,619		25,798
Other Sterile Injectables (4)	43,695		47,567		124,026		161,740
Total Sterile Injectables (3)	$	263,635	$	237,150	$	777,963	$	670,847
Total Generic Pharmaceuticals (5)	$	218,012	$	257,969	$	654,322	$	748,445
Total International Pharmaceuticals (6)	$	30,466	$	30,247	$	87,428	$	108,425
Total revenues, net	$	729,426	$	745,466	$	2,149,564	$	2,160,689

__________


(1)	Products included within Other Specialty are NASCOBAL^®Nasal Spray and AVEED^®. Beginning with our first-quarter 2019 reporting, TESTOPEL^®, which was previously included in Other Specialty, has been reclassified and is now included in the Established Products portfolio for all periods presented.


(2)	Products included within Other Established include, but are not limited to, LIDODERM^®, VOLTAREN^® Gel, EDEX^®, FORTESTA^® Gel and TESTIM^®, including the authorized generics of FORTESTA^® Gel and TESTIM^®.


(3)	Individual products presented above represent the top two performing products in each product category for either the three or nine months ended September 30, 2019 and/or any product having revenues in excess of $25 million during any quarterly period in 2019 or 2018.


(4)	Products included within Other Sterile Injectables include ephedrine sulfate injection and others.

(5)

The Generic Pharmaceuticals segment is comprised of a portfolio of products that are generic versions of branded products, are distributed primarily through the same wholesalers, generally have no intellectual property protection and are sold within the U.S. During the three and nine months ended September 30, 2019, colchicine tablets, the authorized generic of Takeda Pharmaceuticals U.S.A., Inc.’s Colcrys^®, which launched in July 2018, made up 7% and 6% of consolidated total revenue, respectively. No other individual product within this segment has exceeded 5% of consolidated total revenues for the periods presented.

(6)

The International Pharmaceuticals segment, which accounted for 4% of consolidated total revenues during both the three and nine months ended September 30, 2019 and 4% and 5% of consolidated total revenues during the three and nine months ended September 30, 2018, respectively, includes a variety of specialty pharmaceutical products sold outside the U.S., primarily in Canada through our operating company Paladin.

Fair Value Measurements

9 Months Ended

Sep. 30, 2019

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENTS

NOTE 6. FAIR VALUE MEASUREMENTS

Financial Instruments

The financial instruments recorded in our Condensed Consolidated Balance Sheets include cash and cash equivalents (including money market funds), restricted cash and cash equivalents, accounts receivable, equity method investments, accounts payable and accrued expenses, acquisition-related contingent consideration and debt obligations. Included in cash and cash equivalents and restricted cash and cash equivalents are money market funds representing a type of mutual fund required by law to invest in low-risk securities (for example, U.S. government bonds, U.S. Treasury Bills and commercial paper). Money market funds pay dividends that generally reflect short-term interest rates. Due to their short-term maturity, the carrying amounts of non-restricted and restricted cash and cash equivalents (including money market funds), accounts receivable, accounts payable and accrued expenses approximate their fair values.

The following table presents current and noncurrent restricted cash and cash equivalent balances at September 30, 2019 and December 31, 2018 (in thousands):



	September 30, 2019		December 31, 2018
Restricted cash and cash equivalents—current portion (1)	$	222,491	$	305,368
Restricted cash and cash equivalents—noncurrent portion (2)	22,357		22,356
Restricted cash and cash equivalents—total (3)	$	244,848	$	327,724

__________


(1)	These amounts are reported in our Condensed Consolidated Balance Sheets as Restricted cash and cash equivalents.


(2)	These amounts are reported in our Condensed Consolidated Balance Sheets as Other assets.

(3)

Approximately $221.6 million and $299.7 million of our restricted cash and cash equivalents are held in qualified settlement funds (QSFs) for mesh-related matters at September 30, 2019 and December 31, 2018, respectively. The remaining amount of restricted cash and cash equivalents at September 30, 2019 primarily relates to other litigation-related matters. See Note 13. Commitments and Contingencies for further information.

Fair value guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:


•	Level 1—Quoted prices in active markets for identical assets or liabilities.


•	Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.


•	Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Acquisition-Related Contingent Consideration

The fair value of contingent consideration liabilities is determined using unobservable inputs; hence, these instruments represent Level 3 measurements within the above-defined fair value hierarchy. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period, the contingent consideration liability is remeasured at current fair value with changes recorded in earnings. Changes in any of these estimated inputs used as of the date of this report could have resulted in significant adjustments to fair value. See the “Recurring Fair Value Measurements” section below for additional information on acquisition-related contingent consideration.

Recurring Fair Value Measurements

The Company’s financial assets and liabilities measured at fair value on a recurring basis at September 30, 2019 and December 31, 2018 were as follows (in thousands):



	Fair Value Measurements at September 30, 2019 using:
	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Assets:
Money market funds	$	748,441	$	—	$	—	$	748,441
Liabilities:
Acquisition-related contingent consideration—current	$	—	$	—	$	20,974	$	20,974
Acquisition-related contingent consideration—noncurrent	$	—	$	—	$	38,520	$	38,520



	Fair Value Measurements at December 31, 2018 using:
	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Assets:
Money market funds	$	137,215	$	—	$	—	$	137,215
Liabilities:
Acquisition-related contingent consideration—current	$	—	$	—	$	36,514	$	36,514
Acquisition-related contingent consideration—noncurrent	$	—	$	—	$	80,189	$	80,189

At September 30, 2019 and December 31, 2018, money market funds include $54.6 million and $86.9 million, respectively, in QSFs to be disbursed to mesh-related or other product liability claimants. Amounts in QSFs are considered restricted cash equivalents. See Note 13. Commitments and Contingencies for further discussion of our product liability cases. At September 30, 2019 and December 31, 2018, the differences between the amortized cost and the fair value of our money market funds were not material, individually or in the aggregate.

Fair Value Measurements Using Significant Unobservable Inputs

The following table presents changes to the Company’s liability for acquisition-related contingent consideration, which is measured at fair value on a recurring basis using significant unobservable inputs (Level 3), for the three and nine months ended September 30, 2019 and 2018 (in thousands):



	Three Months Ended September 30,						Nine Months Ended September 30,
	2019			2018			2019			2018
Beginning of period	$	52,930		$	152,098		$	116,703		$	190,442
Amounts settled	(9,376		)	(24,564		)	(30,541		)	(73,298		)
Changes in fair value recorded in earnings	16,025			769			(26,983		)	11,731
Effect of currency translation	(85		)	167			315			(405		)
End of period	$	59,494		$	128,470		$	59,494		$	128,470

At September 30, 2019, the fair value measurements of the contingent consideration obligations were determined using risk-adjusted discount rates ranging from approximately 9.5% to 15.0% (weighted average rate of approximately 11.8%). Changes in fair value recorded in earnings related to acquisition-related contingent consideration are included in our Condensed Consolidated Statements of Operations as Acquisition-related and integration items. Amounts recorded for the current and noncurrent portions of acquisition-related contingent consideration are included in Accounts payable and accrued expenses and Other liabilities, respectively, in our Condensed Consolidated Balance Sheets.

The following table presents changes to the Company’s liability for acquisition-related contingent consideration during the nine months ended September 30, 2019 by acquisition (in thousands):



	Balance as of December 31, 2018		Changes in Fair Value Recorded in Earnings			Amounts Settled and Other			Balance as of September 30, 2019
Auxilium acquisition	$	14,157	$	1,086		$	(388	)	$	14,855
Lehigh Valley Technologies, Inc. acquisitions	34,700		10,566			(14,466		)	30,800
VOLTAREN® Gel acquisition (1)	56,240		(37,395		)	(14,601		)	4,244
Other	11,606		(1,240		)	(771		)	9,595
Total	$	116,703	$	(26,983	)	$	(30,226	)	$	59,494

__________


(1)	The change in fair value recorded in earnings includes the impact of certain competitive events occurring during the nine months ended September 30, 2019.

Nonrecurring Fair Value Measurements

The Company’s financial assets and liabilities measured at fair value on a nonrecurring basis during the nine months ended September 30, 2019 were as follows (in thousands):



	Fair Value Measurements during the Nine Months Ended September 30, 2019 (1) using:						Total Expense for the Nine Months Ended September 30, 2019
	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Expense for the Nine Months Ended September 30, 2019
Assets:
Intangible assets, excluding goodwill (Note 9)	$	—	$	—	$	41,839	$	(104,660	)
Certain property, plant and equipment	—		—		—		(2,884		)
Total	$	—	$	—	$	41,839	$	(107,544	)

__________


(1)	The fair value amounts are presented as of the date of the fair value measurement as these assets are not measured at fair value on a recurring basis. Such measurements generally occur in connection with our quarter-end financial reporting close procedures.

Additionally, the Company recorded aggregate pre-tax non-cash goodwill impairment charges during the nine months ended September 30, 2019 of $151.1 million. Refer to Note 9. Goodwill and Other Intangibles for further description, including the valuation methodologies utilized.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Leases

9 Months Ended

Sep. 30, 2019

Leases [Abstract]

LEASES

NOTE 8. LEASES

We have entered into contracts with third parties to lease a variety of assets, including certain real estate, machinery, equipment, automobiles and other assets.

Our leases frequently allow for lease payments that could vary based on factors such as inflation or the degree of utilization of the underlying asset and the incurrence of contractual charges such as those for common area maintenance or utilities.

Renewal and/or early termination options are common in our lease arrangements, particularly with respect to our real estate leases. Our ROU assets and lease liabilities generally exclude periods covered by renewal options and include periods covered by early termination options (based on our conclusion that it is not reasonably certain that we will exercise such options).

Our most significant lease is for our U.S. headquarters in Malvern, Pennsylvania. The initial term of the lease is through 2024 and includes three renewal options, each for an additional 60-month period. These renewal options are not considered reasonably certain of exercise and are therefore excluded from the ROU asset and lease liability.

We are party to certain sublease arrangements, primarily related to our real estate leases, where we act as the lessee and intermediate lessor. For example, we sublease portions of our Malvern, Pennsylvania facility to multiple tenants through sublease arrangements ending in 2024, with certain limited renewal and early termination options.

The following table presents information about the Company's ROU assets and lease liabilities at September 30, 2019 (in thousands):



	Condensed Consolidated Balance Sheets Line Items	September 30, 2019
ROU assets:
Operating lease ROU assets	Operating lease assets	$	53,839
Finance lease ROU assets	Property, plant and equipment, net	59,104
Total ROU assets		$	112,943
Operating lease liabilities:
Current operating lease liabilities	Current portion of operating lease liabilities	$	10,575
Noncurrent operating lease liabilities	Operating lease liabilities, less current portion	50,965
Total operating lease liabilities		$	61,540
Finance lease liabilities:
Current finance lease liabilities	Accounts payable and accrued expenses	$	5,550
Noncurrent finance lease liabilities	Other liabilities	32,768
Total finance lease liabilities		$	38,318

The following table presents information about lease costs and expenses and sublease income for the three and nine months ended September 30, 2019 (in thousands):



	Condensed Consolidated Statements of Operations Line Items	Three Months Ended September 30, 2019			Nine Months Ended September 30, 2019
Operating lease cost	Various (1)	$	3,510		$	10,269
Finance lease cost:
Amortization of ROU assets	Various (1)	$	2,311		$	7,096
Interest on lease liabilities	Interest expense, net	$	271		$	1,256
Other lease costs and income:
Variable lease costs (2)	Various (1)	$	2,318		$	7,185
Sublease income	Various (1)	$	(932	)	$	(2,828	)

__________


(1)	Amounts are included in the Condensed Consolidated Statements of Operations based on the function that the underlying leased asset supports. The following table presents the components of such aggregate amounts for the three and nine months ended September 30, 2019 (in thousands):



	Three Months Ended September 30, 2019		Nine Months Ended September 30, 2019
Cost of revenues	$	2,793	$	8,425
Selling, general and administrative	$	4,347	$	13,145
Research and development	$	67	$	152


(2)	Amounts represent variable lease costs incurred that were not included in the initial measurement of the lease liability, such as common area maintenance and utilities costs associated with leased real estate and certain costs associated with our automobile leases.

The following table, determined in accordance with ASC 842, provides the undiscounted amount of future cash flows included in our lease liabilities at September 30, 2019 for each of the five years subsequent to December 31, 2018 and thereafter, as well as a reconciliation of such undiscounted cash flows to our lease liabilities at September 30, 2019 (in thousands):



	Operating Leases		Finance Leases
2019, excluding amounts already paid	$	3,740	$	1,826
2020	13,771		7,447
2021	13,996		7,594
2022	12,424		7,744
2023	10,012		7,898
Thereafter	20,549		21,881
Total future lease payments	$	74,492	$	54,390
Less: amount representing interest	12,952		16,072
Present value of future lease payments (lease liability)	$	61,540	$	38,318

The Company’s future minimum lease commitments as of December 31, 2018 under ASC 840, as reported in the Annual Report, were as follows:



	Capital Leases (1)		Operating Leases
2019	$	6,884	$	15,800
2020	6,819		14,519
2021	6,921		12,883
2022	7,072		12,454
2023	7,225		9,945
Thereafter	9,127		20,573
Total minimum lease payments	$	44,048	$	86,174
Less: Amount representing interest	4,084
Total present value of minimum payments	$	39,964
Less: Current portion of such obligations	5,845
Long-term capital lease obligations	$	34,119

__________


(1)	The Malvern, Pennsylvania headquarters lease arrangement is included under Capital Leases.

The following table provides the weighted average remaining lease term and weighted average discount rates for our leases as of September 30, 2019:



	September 30, 2019
Weighted average remaining lease term (years), weighted based on lease liability balances:
Operating leases	6.0 years
Finance leases	9.7 years
Weighted average discount rate (percentages), weighted based on the remaining balance of lease payments:
Operating leases	5.8	%
Finance leases	5.5	%

The following table provides certain cash flow and supplemental noncash information related to our lease liabilities for the nine months ended September 30, 2019 (in thousands):



	Nine Months Ended September 30, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash payments for operating leases	$	11,200
Operating cash payments for finance leases	$	1,535
Financing cash payments for finance leases	$	7,826
Lease liabilities arising from obtaining right-of-use assets:
Operating leases	$	623
Finance leases	$	5,901

LEASES

NOTE 8. LEASES

We have entered into contracts with third parties to lease a variety of assets, including certain real estate, machinery, equipment, automobiles and other assets.

The following table presents information about the Company's ROU assets and lease liabilities at September 30, 2019 (in thousands):



	Condensed Consolidated Balance Sheets Line Items	September 30, 2019
ROU assets:
Operating lease ROU assets	Operating lease assets	$	53,839
Finance lease ROU assets	Property, plant and equipment, net	59,104
Total ROU assets		$	112,943
Operating lease liabilities:
Current operating lease liabilities	Current portion of operating lease liabilities	$	10,575
Noncurrent operating lease liabilities	Operating lease liabilities, less current portion	50,965
Total operating lease liabilities		$	61,540
Finance lease liabilities:
Current finance lease liabilities	Accounts payable and accrued expenses	$	5,550
Noncurrent finance lease liabilities	Other liabilities	32,768
Total finance lease liabilities		$	38,318

The following table presents information about lease costs and expenses and sublease income for the three and nine months ended September 30, 2019 (in thousands):



	Condensed Consolidated Statements of Operations Line Items	Three Months Ended September 30, 2019			Nine Months Ended September 30, 2019
Operating lease cost	Various (1)	$	3,510		$	10,269
Finance lease cost:
Amortization of ROU assets	Various (1)	$	2,311		$	7,096
Interest on lease liabilities	Interest expense, net	$	271		$	1,256
Other lease costs and income:
Variable lease costs (2)	Various (1)	$	2,318		$	7,185
Sublease income	Various (1)	$	(932	)	$	(2,828	)

__________


(1)	Amounts are included in the Condensed Consolidated Statements of Operations based on the function that the underlying leased asset supports. The following table presents the components of such aggregate amounts for the three and nine months ended September 30, 2019 (in thousands):



	Three Months Ended September 30, 2019		Nine Months Ended September 30, 2019
Cost of revenues	$	2,793	$	8,425
Selling, general and administrative	$	4,347	$	13,145
Research and development	$	67	$	152


(2)	Amounts represent variable lease costs incurred that were not included in the initial measurement of the lease liability, such as common area maintenance and utilities costs associated with leased real estate and certain costs associated with our automobile leases.



	Operating Leases		Finance Leases
2019, excluding amounts already paid	$	3,740	$	1,826
2020	13,771		7,447
2021	13,996		7,594
2022	12,424		7,744
2023	10,012		7,898
Thereafter	20,549		21,881
Total future lease payments	$	74,492	$	54,390
Less: amount representing interest	12,952		16,072
Present value of future lease payments (lease liability)	$	61,540	$	38,318

The Company’s future minimum lease commitments as of December 31, 2018 under ASC 840, as reported in the Annual Report, were as follows:



	Capital Leases (1)		Operating Leases
2019	$	6,884	$	15,800
2020	6,819		14,519
2021	6,921		12,883
2022	7,072		12,454
2023	7,225		9,945
Thereafter	9,127		20,573
Total minimum lease payments	$	44,048	$	86,174
Less: Amount representing interest	4,084
Total present value of minimum payments	$	39,964
Less: Current portion of such obligations	5,845
Long-term capital lease obligations	$	34,119

__________


(1)	The Malvern, Pennsylvania headquarters lease arrangement is included under Capital Leases.

The following table provides the weighted average remaining lease term and weighted average discount rates for our leases as of September 30, 2019:



	September 30, 2019
Weighted average remaining lease term (years), weighted based on lease liability balances:
Operating leases	6.0 years
Finance leases	9.7 years
Weighted average discount rate (percentages), weighted based on the remaining balance of lease payments:
Operating leases	5.8	%
Finance leases	5.5	%

The following table provides certain cash flow and supplemental noncash information related to our lease liabilities for the nine months ended September 30, 2019 (in thousands):



	Nine Months Ended September 30, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash payments for operating leases	$	11,200
Operating cash payments for finance leases	$	1,535
Financing cash payments for finance leases	$	7,826
Lease liabilities arising from obtaining right-of-use assets:
Operating leases	$	623
Finance leases	$	5,901

Goodwill and Other Intangibles

9 Months Ended

Sep. 30, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND OTHER INTANGIBLES

NOTE 9. GOODWILL AND OTHER INTANGIBLES

Goodwill

Changes in the carrying amount of our goodwill for the nine months ended September 30, 2019 were as follows (in thousands):



	Branded Pharmaceuticals		Sterile Injectables		Generic Pharmaceuticals			International Pharmaceuticals		Total
Goodwill as of December 31, 2018	$	828,818	$	2,731,193	$	151,108		$	53,517	$	3,764,636
Effect of currency translation	—		—		—			1,794		1,794
Goodwill impairment charges	—		—		(151,108		)	—		(151,108		)
Goodwill as of September 30, 2019	$	828,818	$	2,731,193	$	—		$	55,311	$	3,615,322

The carrying amounts of goodwill at September 30, 2019 and December 31, 2018 are net of the following accumulated impairments (in thousands):



	Branded Pharmaceuticals		Sterile Injectables		Generic Pharmaceuticals		International Pharmaceuticals		Total
Accumulated impairment losses as of December 31, 2018	$	855,810	$	—	$	2,991,549	$	456,408	$	4,303,767
Accumulated impairment losses as of September 30, 2019	$	855,810	$	—	$	3,142,657	$	470,181	$	4,468,648

Other Intangible Assets

Changes in the amount of other intangible assets for the nine months ended September 30, 2019 are set forth in the table below (in thousands).



Cost basis:	Balance as of December 31, 2018			Acquisitions			Impairments			Other (1)			Effect of Currency Translation			Balance as of September 30, 2019
Indefinite-lived intangibles:
In-process research and development	$	93,900		$	—		$	—		$	—		$	—		$	93,900
Total indefinite-lived intangibles	$	93,900		$	—		$	—		$	—		$	—		$	93,900
Finite-lived intangibles:
Licenses (weighted average life of 14 years)	$	457,402		$	—		$	—		$	—		$	—		$	457,402
Tradenames	6,409			—			—			—			—			6,409
Developed technology (weighted average life of 11 years)	6,182,015			—			(104,660		)	(2,196		)	7,443			6,082,602
Total finite-lived intangibles (weighted average life of 11 years)	$	6,645,826		$	—		$	(104,660	)	$	(2,196	)	$	7,443		$	6,546,413
Total other intangibles	$	6,739,726		$	—		$	(104,660	)	$	(2,196	)	$	7,443		$	6,640,313

Accumulated amortization:	Balance as of December 31, 2018			Amortization			Impairments			Other (1)			Effect of Currency Translation			Balance as of September 30, 2019
Finite-lived intangibles:
Licenses	$	(398,182	)	$	(9,726	)	$	—		$	—		$	—		$	(407,908	)
Tradenames	(6,409		)	—			—			—			—			(6,409		)
Developed technology	(2,877,829		)	(408,223		)	—			2,196			(3,923		)	(3,287,779		)
Total other intangibles	$	(3,282,420	)	$	(417,949	)	$	—		$	2,196		$	(3,923	)	$	(3,702,096	)
Net other intangibles	$	3,457,306														$	2,938,217

__________


(1)	Other adjustments relate to the removal of certain fully amortized intangible assets.

Amortization expense for the three and nine months ended September 30, 2019 totaled $131.9 million and $417.9 million, respectively. Amortization expense for the three and nine months ended September 30, 2018 totaled $161.3 million and $471.7 million, respectively. Amortization expense is included in Cost of revenues in the Condensed Consolidated Statements of Operations. Estimated amortization of intangibles for the five fiscal years subsequent to December 31, 2018 is as follows (in thousands):



2019	$	543,795
2020	$	457,248
2021	$	415,637
2022	$	399,886
2023	$	369,619

Impairments

Endo tests goodwill and indefinite-lived intangible assets for impairment annually and whenever events or changes in circumstances indicate that such assets might be impaired. Our annual assessment is performed as of October 1st.

As part of our goodwill and intangible asset impairment assessments, we estimate the fair values of our reporting units and our intangible assets using an income approach that utilizes a discounted cash flow model or, where appropriate, a market approach. The discounted cash flow models are dependent upon our estimates of future cash flows and other factors. These estimates of future cash flows involve assumptions concerning (i) future operating performance, including future sales, long-term growth rates, operating margins, tax rates, variations in the amount and timing of cash flows and the probability of achieving the estimated cash flows and (ii) future economic conditions. These assumptions are based on significant inputs not observable in the market and thus represent Level 3 measurements within the fair value hierarchy. The discount rates applied to the estimated cash flows are based on the overall risk associated with the particular assets and other market factors. We believe the discount rates and other inputs and assumptions are consistent with those that a market participant would use. Any impairment charges resulting from annual or interim goodwill and intangible asset impairment assessments are recorded to Asset impairment charges in our Condensed Consolidated Statements of Operations.

During the three and nine months ended September 30, 2019 and 2018, the Company incurred the following goodwill and other intangible asset impairment charges (in thousands):



	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Goodwill impairment charges	$	—	$	—	$	151,108	$	391,000
Other intangible asset impairment charges	$	4,261	$	140,609	$	104,660	$	217,576

A summary of significant goodwill and other intangible asset impairment tests and related charges is included below. Pre-tax non-cash intangible asset impairment charges related primarily to certain in-process research and development and/or developed technology intangible assets that were tested for impairment following changes in market conditions and certain other factors impacting recoverability.

As a result of certain competitive events that occurred during the first quarter of 2019, we tested the goodwill of our Generic Pharmaceuticals reporting unit for impairment as of March 31, 2019. The fair value of the reporting unit was estimated using an income approach that utilized a discounted cash flow model. The discount rate utilized in this test was 10.5%. This goodwill impairment test resulted in a pre-tax non-cash goodwill impairment charge of $86.0 million during the three months ended March 31, 2019, representing the excess of this reporting unit’s carrying amount over its estimated fair value. This Generic Pharmaceuticals impairment can be primarily attributed to the impact of the competitive events referenced above and an increase in the discount rate used in the determination of fair value.

During the second quarter of the 2019, unfavorable competitive and pricing events occurred that caused us to update certain assumptions from those used in our first-quarter 2019 Generic Pharmaceuticals goodwill impairment test. The Company considered these events, together with the fact that this reporting unit’s carrying amount equaled its fair value immediately subsequent to the first-quarter 2019 goodwill impairment charge, as part of its qualitative assessment of goodwill triggering events for the second quarter of 2019. As a result, we concluded that it was more likely than not that the fair value of this reporting unit was below its carrying amount as of June 30, 2019 and a goodwill impairment test was required. After performing this quantitative test, we determined that this reporting unit’s carrying amount exceeded its estimated fair value. The fair value of the reporting unit was estimated using an income approach that utilized a discounted cash flow model. The discount rate utilized in this test was 10.5%. Based on the excess of this reporting unit’s carrying amount over its estimated fair value, we recorded a pre-tax non-cash goodwill impairment charge of $65.1 million during the three months ended June 30, 2019, representing the entire remaining amount of this reporting unit’s goodwill.

During the first quarter of 2018, a change in segments resulted in changes to our reporting units for goodwill impairment testing purposes, including the creation of a new Sterile Injectables reporting unit, which was previously part of our Generics reporting unit. As a result of these changes, under U.S. GAAP, we tested the goodwill of the former Generics reporting unit immediately before the segment realignment and the goodwill of both the new Sterile Injectables and Generic Pharmaceuticals reporting units immediately after the segment realignment. These goodwill tests were performed using an income approach that utilizes a discounted cash flow model. The results of these goodwill impairment tests were as follows:


•	The former Generics reporting unit’s estimated fair value exceeded its carrying amount, resulting in no related goodwill impairment charge.


•	The new Sterile Injectables reporting unit’s estimated fair value exceeded its carrying amount, resulting in no related goodwill impairment charge.

•

The new Generic Pharmaceuticals reporting unit’s carrying amount exceeded its estimated fair value, resulting in a pre-tax non-cash goodwill impairment charge of $391.0 million.

Contract Assets and Liabilities

9 Months Ended

Sep. 30, 2019

Contract with Customer, Asset and Liability [Abstract]

CONTRACT ASSETS AND LIABILITIES

NOTE 10. CONTRACT ASSETS AND LIABILITIES

Our revenue consists almost entirely of sales of our pharmaceutical products to customers, whereby we ship products to a customer pursuant to a purchase order. Revenue contracts such as these do not generally give rise to contract assets or contract liabilities because: (i) the underlying contracts generally have only a single performance obligation and (ii) we do not generally receive consideration until the performance obligation is fully satisfied. At September 30, 2019, the unfulfilled performance obligations for these types of contracts relate to ordered but undelivered products. We generally expect to fulfill the performance obligations and recognize revenue within one week of entering into the underlying contract. Based on the short-term initial contract duration, additional disclosure about the remaining performance obligations is not required.

Certain of our other revenue-generating contracts, including license and collaboration agreements, may result in contract assets and/or contract liabilities. For example, we may recognize contract liabilities upon receipt of certain upfront and milestone payments from customers when there are remaining performance obligations.

The following table shows the opening and closing balances of contract assets and contract liabilities from contracts with customers (dollars in thousands):



	September 30, 2019		December 31, 2018		$ Change			% Change
Contract assets, net (1)	$	4,283	$	12,065	$	(7,782	)	(65	)%
Contract liabilities, net (2)	$	6,864	$	19,217	$	(12,353	)	(64	)%

__________

(1)

At September 30, 2019 and December 31, 2018, approximately $4.3 million and $9.3 million, respectively, of these contract asset amounts are classified as current assets and are included in Prepaid expenses and other current assets in the Company’s Condensed Consolidated Balance Sheets. The remaining amounts are classified as noncurrent and are included in Other assets. The net decrease in contract assets during the nine months ended September 30, 2019 was primarily due to reclassifications to accounts receivable following the resolution of certain conditions other than the passage of time affecting the Company’s rights to consideration for the sale of certain goods, partially offset by certain sales activity during the period.

(2)

At September 30, 2019 and December 31, 2018, approximately $2.1 million and $1.7 million, respectively, of these contract liability amounts are classified as current liabilities and are included in Accounts payable and accrued expenses in the Company’s Condensed Consolidated Balance Sheets. The remaining amounts are classified as noncurrent and are included in Other liabilities. During the nine months ended September 30, 2019, the Company entered into new contracts resulting in an increase to contract liabilities of approximately $4.0 million. This increase was more than offset by approximately $14.9 million in reductions following certain product discontinuation activities in our International Pharmaceuticals segment and approximately $1.1 million in revenue recognized during the period.

During the nine months ended September 30, 2019, we recognized revenue of $6.7 million relating to performance obligations satisfied, or partially satisfied, in prior periods. Such revenue generally relates to changes in estimates with respect to our variable consideration.

Debt

9 Months Ended

Sep. 30, 2019

Debt Disclosure [Abstract]

DEBT

NOTE 12. DEBT

The following table presents information about the Company’s total indebtedness at September 30, 2019 and December 31, 2018 (dollars in thousands):



	September 30, 2019						December 31, 2018
	Effective Interest Rate		Principal Amount		Carrying Amount		Effective Interest Rate		Principal Amount		Carrying Amount
7.25% Senior Notes due 2022	7.25	%	$	8,294	$	8,294	7.91	%	$	400,000	$	392,947
5.75% Senior Notes due 2022	5.75	%	182,479		182,479		6.04	%	700,000		694,464
5.375% Senior Notes due 2023	5.62	%	210,440		208,912		5.62	%	750,000		743,438
6.00% Senior Notes due 2023	6.28	%	1,439,840		1,426,195		6.28	%	1,635,000		1,616,817
5.875% Senior Secured Notes due 2024	6.14	%	300,000		296,497		6.14	%	300,000		296,062
6.00% Senior Notes due 2025	6.27	%	1,200,000		1,185,135		6.27	%	1,200,000		1,183,415
7.50% Senior Secured Notes due 2027	7.71	%	1,500,000		1,481,758				—		—
Term Loan B Facility Due 2024	6.59	%	3,338,162		3,309,791		7.02	%	3,363,775		3,331,276
Revolving Credit Facility	4.63	%	300,000		300,000				—		—
Total long-term debt, net			$	8,479,215	$	8,399,061			$	8,348,775	$	8,258,419
Less current portion, net			34,150		34,150				34,150		34,150
Total long-term debt, less current portion, net			$	8,445,065	$	8,364,911			$	8,314,625	$	8,224,269

The Company and its subsidiaries, with certain customary exceptions, guarantee or serve as issuers or borrowers of the debt instruments representing substantially all of the Company’s indebtedness at September 30, 2019. The obligations under (i) all of the senior secured notes and (ii) the Credit Agreement (as defined below) and related loan documents are secured on a pari passu basis by a perfected first priority (subject to certain permitted liens) lien on the collateral securing such instruments, which collateral represents substantially all of the assets of the issuers or borrowers and the guarantors party thereto (subject to customary exceptions). Our senior unsecured notes are unsecured and effectively subordinated in right of priority to our credit agreement and our senior secured notes, in each case to the extent of the value of the collateral securing such instruments.

The aggregate estimated fair value of the Company’s long-term debt, which was estimated using inputs based on quoted market prices for the same or similar debt issuances, was $6.9 billion and $7.2 billion at September 30, 2019 and December 31, 2018, respectively. Based on this valuation methodology, we determined these debt instruments represent Level 2 measurements within the fair value hierarchy.

Senior Notes and Senior Secured Notes

At September 30, 2019 and December 31, 2018, we were in compliance with all covenants contained in the indentures governing our various senior notes and senior secured notes.

Credit Facilities

The credit facilities consist of a $1,000.0 million revolving credit facility (the Revolving Credit Facility) and a senior secured term loan facility (the Term Loan Facility and, together with the Revolving Credit Facility, the Credit Facilities). In June 2019, the Company borrowed $300.0 million under the Revolving Credit Facility. The proceeds will be used for purposes consistent with the Company’s capital allocation priorities, including for general corporate purposes.

After giving effect to this transaction and previously issued and outstanding letters of credit, approximately $696.8 million of remaining credit is available under the Revolving Credit Facility. However, the Company’s debt agreements contain certain conditions that limit the Company’s ability to incur additional secured indebtedness, including borrowings under the Revolving Credit Facility, which significantly restrict the Company’s access to this remaining available credit.

At September 30, 2019 and December 31, 2018, we were in compliance with all covenants contained in the Credit Agreement (as defined below).

March 2019 Refinancing

In March 2019, the Company executed several transactions (the March 2019 Refinancing Transactions), which included:


•	the entry into an amendment (the Revolving Credit Facility Amendment) to the Company’s existing credit agreement, which was originally dated April 27, 2017 (the Credit Agreement);


•	the issuance of $1,500.0 million of 7.50% Senior Secured Notes due 2027 (the 2027 Notes);


•	the repurchase of $1,642.2 million aggregate principal amount of certain of the Company’s senior unsecured notes for $1,500.0 million in cash, excluding accrued interest (the Notes Repurchases); and


•	the solicitation of consents from the holders of the existing 7.25% Senior Notes due 2022 and 5.75% Senior Notes due 2022 (together, the Consent Notes) to certain amendments to the indentures governing such notes, which eliminated substantially all of the restrictive covenants, certain events of default and other provisions contained in each such indenture.

The Revolving Credit Facility Amendment amended the Credit Agreement to, among other things, (i) extend the maturity of the commitments under the Revolving Credit Facility from April 2022 to March 2024 (with the exception of $76.0 million of commitments that were not extended), (ii) provide greater covenant flexibility by increasing the maximum Secured Net Leverage Ratio described in the Financial Covenant (as defined in the Credit Agreement) from 3.50:1.00 to 4.50:1.00 and (iii) limit the scenarios under which such Financial Covenant will be tested.

The 2027 Notes were issued by Par Pharmaceutical, Inc. (PPI), a wholly-owned indirect subsidiary of the Company, in a private offering to “qualified institutional buyers” (as defined in Rule 144A under the Securities Act) and outside the U.S. to non-U.S. persons in compliance with Regulation S under the Securities Act. The 2027 Notes are guaranteed on a senior secured basis by the Company and its subsidiaries that also guarantee the Credit Agreement (collectively, the Guarantors). The 2027 Notes are senior secured obligations of PPI and the Guarantors and are secured by the same collateral that secures the Credit Agreement and the Company’s existing senior secured notes. Interest on the 2027 Notes is payable semiannually in arrears on April 1 and October 1 of each year, beginning on October 1, 2019.

The 2027 Notes will mature on April 1, 2027; however, the indenture governing these notes allows for redemption prior to maturity, in whole or in part, subject to certain restrictions and limitations described therein, in the following ways:


•	Before April 1, 2022, the 2027 Notes may be redeemed, in whole or in part, by paying the sum of: (i) 100% of the principal amount being redeemed, (ii) an applicable make-whole premium as described in the indenture and (iii) accrued and unpaid interest, if any, to, but not including, the date of redemption.

•

On or after April 1, 2022, the 2027 Notes may be redeemed, in whole or in part, at redemption prices set forth in the indenture, plus accrued and unpaid interest, if any, to, but not including, the date of redemption. The redemption prices for the 2027 Notes vary over time pursuant to a step-down schedule set forth in the indenture, beginning at 105.625% of the principal amount redeemed and decreasing to 100% by April 1, 2025.


•	Before April 1, 2022, the 2027 Notes may be redeemed, in part (up to 35% of the principal amount outstanding), with the net cash proceeds from specified equity offerings at 107.500% of the principal amount redeemed, plus accrued and unpaid interest, if any, to, but not including, the date of redemption.

The 2027 Notes indenture contains covenants that, among other things, restrict the Company’s ability and the ability of its Restricted Subsidiaries (as defined in the indenture) to incur certain additional indebtedness and issue preferred stock; make certain dividends, distributions, investments and other restricted payments; sell certain assets; enter into sale and leaseback transactions; agree to certain restrictions on the ability of restricted subsidiaries to make certain payments to the Company or any of its restricted subsidiaries; create certain liens; merge, consolidate or sell all or substantially all of the Company’s assets; enter into certain transactions with affiliates or designate subsidiaries as unrestricted subsidiaries. These covenants are subject to a number of exceptions and qualifications, including the fall away or revision of certain of these covenants and release of collateral upon the 2027 Notes receiving investment grade credit ratings.

The Company used the net proceeds of the 2027 Notes and cash on hand primarily to fund the Notes Repurchases and to pay certain premiums, fees and expenses related thereto. The Notes Repurchases were completed by Endo Finance LLC (Endo Finance), a wholly-owned subsidiary of the Company, pursuant to a tender offer to repurchase portions of the Company’s outstanding 7.25% Senior Notes due 2022, 5.75% Senior Notes due 2022, 5.375% Senior Notes due 2023 and 6.00% Senior Notes due 2023. In connection with the Notes Repurchases, Endo Finance repurchased $1,642.2 million of senior unsecured note indebtedness, representing the aggregate principal amount repurchased, for $1,500.0 million in cash (including certain cash premiums related thereto). The $1,642.2 million aggregate repurchase amount consisted of (i) $389.9 million aggregate principal amount of the 7.25% Senior Notes due 2022, (ii) $517.5 million aggregate principal amount of the 5.75% Senior Notes due 2022, (iii) $539.6 million aggregate principal amount of the 5.375% Senior Notes due 2023 and (iv) $195.2 million aggregate principal amount of the 6.00% Senior Notes due 2023. The aggregate carrying amount of notes repurchased was $1,624.0 million. In conjunction with the Notes Repurchases, Endo Finance also solicited consents from holders of the Consent Notes to certain proposed amendments to the applicable indentures under which each series of Consent Notes were issued, which would eliminate substantially all restrictive covenants, certain events of default and certain other provisions contained in each such indenture. The proposed amendments were effected pursuant to a supplemental indenture to each such indenture executed by Endo Finance and the guarantors of the Consent Notes, which became operative upon the repurchase of at least the requisite consent amount of the applicable series of Consent Notes tendered.

The difference between the cash paid and the carrying amount of notes repurchased in the Notes Repurchases resulted in a $124.0 million gain recorded as Gain on extinguishment of debt in the Condensed Consolidated Statements of Operations. In connection with the March 2019 Refinancing Transactions, we also incurred costs and fees totaling $26.2 million, of which $4.2 million related to the Notes Repurchases, $19.1 million related to the 2027 Notes issuance and $2.9 million related to the Revolving Credit Facility Amendment. The costs incurred in connection with the Notes Repurchases were charged to expense in the first quarter of 2019 and recorded as an offset to the Gain on extinguishment of debt. The costs incurred in connection with the 2027 Notes issuance and the Revolving Credit Facility Amendment, together with previously deferred debt issuance costs associated with the Revolving Credit Facility, have been deferred and will be amortized as interest expense over the terms of the respective instruments.

Maturities

The following table presents the maturities on our long-term debt for each of the five fiscal years subsequent to December 31, 2018 (in thousands):



	Maturities (1)
2019	$	34,150
2020	$	34,150
2021	$	34,150
2022 (2)	$	247,723
2023	$	1,684,430

__________

(1)

Certain amounts borrowed pursuant to the Credit Facilities will immediately mature if certain of our senior notes are not refinanced or repaid in full prior to the date that is 91 days prior to the respective stated maturity dates thereof. Accordingly, we may seek to repay or refinance certain senior notes prior to their stated maturity dates. The amounts in this maturities table do not reflect any such early repayment or refinancing; rather, they reflect stated maturity dates.

(2)

This amount includes $22.8 million, representing the portion of our borrowing under the Revolving Credit Facility associated with the commitments that were not extended in connection with the March 2019 Refinancing Transactions.

Commitments And Contingencies

9 Months Ended

Sep. 30, 2019

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 13. COMMITMENTS AND CONTINGENCIES

Legal Proceedings and Investigations

We and certain of our subsidiaries are involved in various claims, legal proceedings and internal and governmental investigations (collectively, proceedings) that arise from time to time, including, among others, those relating to product liability, intellectual property, regulatory compliance, consumer protection, tax and commercial matters. While we cannot predict the outcome of these proceedings and we intend to vigorously prosecute or defend our position as appropriate, there can be no assurance that we will be successful or obtain any requested relief, and an adverse outcome in any of these proceedings could have a material adverse effect on our business, financial condition, results of operations and cash flows. Matters that are not being disclosed herein are, in the opinion of our management, immaterial both individually and in the aggregate with respect to our financial position, results of operations and cash flows. If and when such matters, in the opinion of our management, become material, either individually or in the aggregate, we will disclose them.

We believe that certain settlements and judgments, as well as legal defense costs, relating to certain product liability or other matters are or may be covered in whole or in part under our insurance policies with a number of insurance carriers. In certain circumstances, insurance carriers reserve their rights to contest or deny coverage. We intend to contest vigorously any and all disputes with our insurance carriers and to enforce our rights under the terms of our insurance policies. Accordingly, we will record receivables with respect to amounts due under these policies only when the realization of the potential claim for recovery is considered probable. Amounts recovered under our insurance policies could be materially less than stated coverage limits and may not be adequate to cover damages, other relief and/or costs relating to claims. In addition, there is no guarantee that insurers will pay claims or that coverage will otherwise be available.

As of September 30, 2019, our accrual for loss contingencies totaled $684.1 million, the most significant components of which relate to product liability and related matters associated with vaginal mesh and testosterone. Although we believe there is a reasonable possibility that a loss in excess of the amount recognized exists, we are unable to estimate the possible loss or range of loss in excess of the amount recognized at this time. As of September 30, 2019, $674.9 million of our accrual for loss contingencies is classified in the Current portion of legal settlement accrual in the Condensed Consolidated Balance Sheets, with the remainder classified as Long-term legal settlement accrual, less current portion. However, the timing of the resolution of certain of these matters remains uncertain.

Product Liability and Related Matters

We and certain of our subsidiaries have been named as defendants in numerous lawsuits in various U.S. federal and state courts, as well as in Canada and other countries, alleging personal injury resulting from the use of certain products of our subsidiaries. These and other related matters are described below in more detail.

Vaginal Mesh. Since 2008, we and certain of our subsidiaries, including American Medical Systems Holdings, Inc. (subsequently converted to Astora Women’s Health Holding LLC and merged into Astora Women’s Health LLC and referred to herein as AMS and/or Astora), have been named as defendants in multiple lawsuits in various state and federal courts in the U.S. (including a federal multidistrict litigation (MDL) pending in the U.S. District Court for the Southern District of West Virginia (MDL No. 2325)), and in Canada and other countries, alleging personal injury resulting from the use of transvaginal surgical mesh products designed to treat pelvic organ prolapse (POP) and stress urinary incontinence (SUI). In January 2018, a representative proceeding (class action) was filed in the Federal Court of Australia against American Medical Systems, LLC. In the various class action and individual complaints, plaintiffs claim a variety of personal injuries, including chronic pain, incontinence, inability to control bowel function and permanent deformities, and seek compensatory and punitive damages, where available.

We and certain plaintiffs’ counsel representing mesh-related product liability claimants have entered into various Master Settlement Agreements (MSAs) and other agreements to resolve up to approximately 71,000 filed and unfiled mesh claims handled or controlled by the participating counsel. These MSAs and other agreements were entered into at various times between June 2013 and the present, were solely by way of compromise and settlement and were not in any way an admission of liability or fault by us or any of our subsidiaries.

All MSAs are subject to a process that includes guidelines and procedures for administering the settlements and the release of funds. In certain cases, the MSAs provide for the creation of QSFs into which funds may be deposited pursuant to certain schedules set forth in those agreements. All MSAs have participation requirements regarding the claims represented by each law firm party to the MSA. In addition, one agreement gives us a unilateral right of approval regarding which claims may be eligible to participate under that settlement. To the extent fewer claims than are authorized under an agreement participate, the total settlement payment under that agreement will be reduced by an agreed-upon amount for each such non-participating claim. Funds deposited in QSFs are considered restricted cash and/or restricted cash equivalents.

Distribution of funds to any individual claimant is conditioned upon the receipt of documentation substantiating the validity of the claim, a full release and dismissal of the entire action or claim as to all AMS parties and affiliates. Prior to receiving funds, an individual claimant is required to represent and warrant that liens, assignment rights or other claims identified in the claims administration process have been or will be satisfied by the individual claimant. Confidentiality provisions apply to the amount of settlement awards to participating claimants, the claims evaluation process and procedures used in conjunction with award distributions, and the negotiations leading to the settlements.

In October 2019, the Ontario Superior Court of Justice approved a class action settlement covering unresolved claims by Canadian women implanted with an AMS vaginal mesh device.

The following table presents the changes in the QSFs and mesh liability accrual balances during the nine months ended September 30, 2019 (in thousands):



	Qualified Settlement Funds			Mesh Liability Accrual
Balance as of January 1, 2019	$	299,733		$	748,606
Additional charges	—			30,000
Cash contributions to Qualified Settlement Funds	185,745			—
Cash distributions to settle disputes from Qualified Settlement Funds	(266,958		)	(266,958		)
Cash distributions to settle disputes	—			(13,334		)
Other (1)	3,125			3,256
Balance as of September 30, 2019	$	221,645		$	501,570

__________


(1)	Amounts deposited in the QSFs may earn interest, which is generally used to pay administrative costs of the fund and is reflected in the table above as an increase to the QSF and Mesh Liability Accrual balances. Any interest remaining after all claims have been paid will generally be distributed to the claimants who participated in that settlement.

Charges related to vaginal mesh liability and associated legal fees and other expenses for all periods presented are reported in Discontinued operations, net of tax in our Condensed Consolidated Statements of Operations.

To date, the Company has made total mesh liability payments of approximately $3.5 billion, $221.6 million of which remains in the QSFs as of September 30, 2019. We currently expect to fund into the QSFs the remaining payments under all settlement agreements during 2019 and 2020. As the funds are disbursed out of the QSFs from time to time, the liability accrual will be reduced accordingly with a corresponding reduction to restricted cash and cash equivalents. In addition, we may pay cash distributions to settle disputes separate from the QSFs, which will also decrease the liability accrual and decrease cash and cash equivalents.

We were contacted in October 2012 regarding a civil investigation initiated by various state attorneys general into mesh products, including transvaginal surgical mesh products designed to treat POP and SUI. In November 2013, we received a subpoena relating to this investigation from the state of California, and we have subsequently received additional subpoenas from California and other states. We are cooperating with the investigations.

We will continue to vigorously defend any unresolved claims and to explore other options as appropriate in our best interests. Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any additional losses that could be incurred.

Although the Company believes it has appropriately estimated the probable total amount of loss associated with all mesh-related matters as of the date of this report, litigation is ongoing in certain cases that have not settled, trials may occur as early as December 2019, and it is reasonably possible that further claims may be filed or asserted and that adjustments to our overall liability accrual may be required. This could have a material adverse effect on our business, financial condition, results of operations and cash flows.

Testosterone. Various manufacturers of prescription medications containing testosterone, including our subsidiaries Endo Pharmaceuticals Inc. (EPI) and Auxilium Pharmaceuticals, Inc. (subsequently converted to Auxilium Pharmaceuticals, LLC and hereinafter referred to as Auxilium), have been named as defendants in multiple lawsuits alleging personal injury resulting from the use of such medications, including FORTESTA^® Gel, DELATESTRYL^®, TESTIM^®, TESTOPEL^®, AVEED^® and STRIANT^®. Plaintiffs in these suits have generally alleged various personal injuries, including pulmonary embolism, stroke or other vascular and/or cardiac injuries, and sought compensatory and/or punitive damages, where available.

As of October 29, 2019, we were aware of approximately 882 testosterone cases (some of which may have been filed on behalf of multiple plaintiffs) pending against one or more of our subsidiaries. These cases have been coordinated in a federal MDL pending in the U.S. District Court for the Northern District of Illinois (MDL No. 2545).

In June 2018, counsel for plaintiffs, on the one hand, and Auxilium and EPI, on the other, executed an MSA allowing for the resolution of all known testosterone replacement therapy product liability claims against our subsidiaries. The MSA was solely by way of compromise and settlement and was not in any way an admission of fault by us or any of our subsidiaries.

The MSA is subject to a process that includes guidelines and procedures for administering the settlement and the release of funds. Among other things, the MSA provides for the creation of a QSF into which the settlement funds will be deposited, establishes participation requirements and allows for a reduction of the total settlement payment in the event the participation threshold is not met. Distribution of funds to any individual claimant is conditioned upon the receipt of documentation substantiating product use and injury as determined by a third-party special master, the dismissal of any lawsuit and the release of the claim as to us and all affiliates. Prior to receiving funds, an individual claimant must represent and warrant that liens, assignment rights or other claims identified in the claims administration process have been or will be satisfied by the individual claimant. Confidentiality provisions apply to the settlement funds, amounts allocated to individual claimants and other terms of the agreement.

The MDL also included a lawsuit filed in November 2014 in the U.S. District for the Northern District of Illinois against EPI, Auxilium and various other manufacturers of testosterone products on behalf of a proposed class of health insurance companies and other third party payers. This lawsuit is not part of the settlement described above. After a series of motions to dismiss, plaintiff filed a third amended complaint in April 2016, asserting civil claims for alleged violations of the Racketeer Influenced and Corrupt Organizations Act and negligent misrepresentation based on defendants’ marketing of certain testosterone products. The court denied a motion to dismiss this complaint in August 2016. In July 2018, the court denied plaintiff’s motion for class certification. In February 2019, the court granted defendants’ motion for summary judgment. Plaintiff’s appeal to the U.S. Court of Appeals for the Seventh Circuit remains pending.

Although the Company believes it has appropriately estimated the probable total amount of loss associated with testosterone-related matters as of the date of this report, it is reasonably possible that further claims may be filed or asserted and that adjustments to our overall liability accrual may be required. This could have a material adverse effect on our business, financial condition, results of operations and cash flows.

Opioid-Related Matters

Since 2014, multiple U.S. states, counties, other governmental persons or entities and private plaintiffs have filed suit against us and/or certain of our subsidiaries, including Endo Health Solutions Inc. (EHSI), EPI, PPI, Par Pharmaceutical Companies, Inc. (PPCI), Endo Generics Holdings, Inc. (EGHI), Vintage Pharmaceuticals, LLC, Generics Bidco I, LLC and DAVA Pharmaceuticals, LLC, as well as various other manufacturers, distributors, pharmacies and/or others, asserting claims relating to defendants’ alleged sales, marketing and/or distribution practices with respect to prescription opioid medications, including certain of our products. As of October 29, 2019, the cases of which we were aware include, but are not limited to, approximately 18 cases filed by or on behalf of states; approximately 2,500 cases filed by counties, cities, Native American tribes and/or other government-related persons or entities; approximately 240 cases filed by hospitals, health systems, unions, health and welfare funds or other third-party payers and approximately 140 cases filed by individuals. Certain of the cases have been filed as putative class actions. In addition to the litigation in the U.S., in August 2018, an action against Paladin Labs Inc., EPI, the Company and various other manufacturers and distributors was commenced in British Columbia on behalf of a proposed class of all federal, provincial and territorial governments and agencies in Canada that paid healthcare, pharmaceutical and treatment costs related to opioids. In May 2019, two putative class actions were filed in Canada, seeking relief on behalf of Canadian residents who were prescribed opioid medications. One of the actions (filed in Ontario Superior Court) names Paladin Labs Inc., the Company and EPI along with several other defendants, and the other action (filed in Quebec Superior Court) names Paladin Labs Inc. along with several other defendants. In the Quebec action, an amended application was filed in October 2019; among other things, the amended application substituted in a new plaintiff.

Many of the U.S. cases have been coordinated in a federal MDL pending in the U.S. District Court for the Northern District of Ohio (MDL No. 2804). In March 2018, the U.S. Department of Justice (DOJ) filed a statement of interest in the case, and in April 2018 it filed a motion to participate in settlement discussions as a friend of the court, which the MDL court granted. The MDL court has issued various case management and substantive orders in certain cases. The first MDL trial, relating to the claims of two Ohio counties (Track One plaintiffs), was set for October 2019 but did not go forward after most defendants settled. In September 2019, EPI, EHSI, PPI and PPCI executed a settlement agreement with the Track One plaintiffs providing for payments totaling $10 million and up to $1 million of VASOSTRICT^® and/or ADRENALIN^®. Under the settlement agreement, the Track One plaintiffs may be entitled to additional payments in the event of a comprehensive resolution of government-related opioid claims. The settlement agreement was solely by way of compromise and settlement and was not in any way an admission of fault by us or any of our subsidiaries.

Other cases remain pending in various state courts. In some jurisdictions, certain state court cases have been transferred to a single court within their respective state court systems for coordinated pretrial proceedings. The state cases are generally at the pleading and/or discovery stage with certain of these cases scheduled for trial beginning in 2020.

The complaints in the cases assert a variety of claims including, but not limited to, claims for alleged violations of public nuisance, consumer protection, unfair trade practices, racketeering, Medicaid fraud and/or drug dealer liability statutes and/or common law claims for public nuisance, fraud/misrepresentation, strict liability, negligence and/or unjust enrichment. The claims are generally based on alleged misrepresentations and/or omissions in connection with the sale and marketing of prescription opioid medications and/or an alleged failure to take adequate steps to prevent abuse and diversion. Plaintiffs generally seek declaratory and/or injunctive relief; compensatory, punitive and/or treble damages; restitution, disgorgement, civil penalties, abatement, attorneys’ fees, costs and/or other relief.

We will continue to vigorously defend the foregoing matters and to explore other options as appropriate in our best interests. Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred. Adjustments to our overall liability accrual may be required in the future, which could have a material adverse effect on our business, financial condition, results of operations and cash flows.

In addition to the lawsuits described above, the Company and/or its subsidiaries have received certain subpoenas, civil investigative demands (CIDs) and informal requests for information concerning the sale, marketing and/or distribution of prescription opioid medications, including the following:

Various state attorneys general have served subpoenas and/or CIDs on EHSI and/or EPI. We are cooperating with the investigations.

In January 2018, our subsidiary EPI received a federal grand jury subpoena from the U.S. District Court for the Southern District of Florida in connection with an investigation being conducted by the U.S. Attorney’s Office for the Southern District of Florida. The subpoena seeks information related to OPANA^® ER, other oxymorphone products and marketing of opioid medications. We are cooperating with the investigation.

In September 2019, EPI, EHSI, PPI and PPCI received subpoenas from the New York State Department of Financial Services seeking production of certain documents and information regarding the marketing, sale and distribution of opioid medications in New York. We are providing information responsive to these subpoenas.

Similar investigations may be brought by others or the foregoing matters may be expanded or result in litigation. We are unable to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred. Adjustments to our overall liability accrual may be required in the future, which could have a material adverse effect on our business, financial condition, results of operations and cash flows.

Generic Drug Pricing Matters

In December 2014, we received a grand jury subpoena from the Antitrust Division of the DOJ issued by the U.S. District Court for the Eastern District of Pennsylvania addressed to Par Pharmaceuticals. The subpoena requested documents and information focused primarily on product and pricing information relating to the authorized generic version of Lanoxin (digoxin) oral tablets and generic doxycycline products, and on communications with competitors and others regarding those products. We are cooperating with the investigation.

In May 2018, we and our subsidiary PPCI each received a CID from the DOJ in relation to a False Claims Act investigation concerning whether generic pharmaceutical manufacturers engaged in price-fixing and market allocation agreements, paid illegal remuneration and caused the submission of false claims. We are cooperating with the investigation.

Since March 2016, various private plaintiffs and state attorneys general have filed cases against our subsidiary PPI and/or, in some instances, the Company, Generics Bidco I, LLC, DAVA Pharmaceuticals, LLC and/or PPCI, as well as other pharmaceutical manufacturers and, in some instances, other corporate and/or individual defendants, alleging price-fixing and other anticompetitive conduct with respect to generic pharmaceutical products. These cases, which include proposed class actions filed on behalf of direct purchasers, end-payers and indirect purchaser resellers, as well as non-class action suits, have generally been consolidated and/or coordinated for pretrial proceedings in a federal MDL pending in the U.S. District Court for the Eastern District of Pennsylvania under the caption In re Generic Pharmaceuticals Pricing Antitrust Litigation (MDL No. 2724).

The various complaints and amended complaints generally assert claims under federal and/or state antitrust law, state consumer protection statutes and/or state common law, and seek damages, treble damages, civil penalties, disgorgement, declaratory and injunctive relief, costs and attorneys’ fees. Some claims are based on alleged product-specific conspiracies. The allegations relating to our subsidiaries in certain of the various complaints focus primarily on one or more of the following products: amitriptyline, baclofen, budesonide, digoxin, divalproex ER, doxycycline hyclate, doxycycline monohydrate, entecavir, fluoxetine, flutamide, hydroxyurea, labetalol, methimazole, nystatin, omega-3-acid ethyl esters, propranolol and/or zoledronic acid. Other claims allege broader, multiple-product conspiracies involving various combinations of these and/or other products. Under these overarching conspiracy theories, plaintiffs seek to hold all alleged participants in a particular conspiracy jointly and severally liable for all harms caused by the alleged conspiracy, not just harms related to the products manufactured and/or sold by a particular defendant.

The MDL court has issued various case management and substantive orders, including orders denying certain motions to dismiss, and discovery is ongoing.

Other Antitrust Matters

Beginning in November 2013, multiple alleged purchasers of LIDODERM^® filed a number of cases against our subsidiary EPI and other pharmaceutical companies generally alleging that they had entered into an anticompetitive agreement to restrain trade through the settlement of certain patent infringement litigation. The various complaints asserted claims under Sections 1 and 2 of the Sherman Act, state antitrust and consumer protection statutes and/or state common law. Plaintiffs generally sought damages, treble damages, disgorgement of profits, restitution, injunctive relief and attorneys’ fees. The cases were consolidated and/or coordinated in April 2014 in a federal MDL in the U.S. District Court for the Northern District of California (MDL No. 2521). The MDL court certified classes of direct and indirect purchasers in February 2017. EPI settled with certain opt-out retailer plaintiffs in October 2017. In September 2018, the court approved EPI’s settlement with the class plaintiffs and entered judgment dismissing the class cases with prejudice. In connection with the settlements, several indirect purchasers which previously had opted out were permitted to rejoin the class. The class settlement agreements provide for aggregate payments of approximately $100 million. As of October 29, 2019, EPI had paid approximately $90 million of this total, including approximately $60 million in 2018 and $30 million in the first quarter of 2019. The remaining $10 million is included in our accrual for loss contingencies. In September 2019, Blue Cross Blue Shield of Michigan and Blue Care Network of Michigan filed a complaint against EPI and other pharmaceutical companies in the Third Judicial Circuit Court, Wayne County, Michigan, asserting claims substantially similar to those asserted in the MDL. In October 2019, certain defendants removed the case to federal court.

Beginning in June 2014, multiple alleged purchasers of OPANA^® ER filed cases against our subsidiaries EHSI and EPI and other pharmaceutical companies, including Impax Laboratories, LLC (formerly Impax Laboratories, Inc. and referred to herein as Impax) and Penwest Pharmaceuticals Co., which our subsidiary EPI had acquired. Some cases were filed on behalf of putative classes of direct and indirect purchasers, while others were filed on behalf of individual retailers or health care benefit plans. All cases have been consolidated and/or coordinated for pretrial proceedings in a federal MDL pending in the U.S. District Court for the Northern District of Illinois (MDL No. 2580). Plaintiffs generally allege that an agreement reached by EPI and Impax to settle patent infringement litigation concerning multiple patents pertaining to OPANA^® ER and EPI’s introduction of reformulated OPANA^® ER violated antitrust laws. The various complaints assert claims under Sections 1 and 2 of the Sherman Act, state antitrust and consumer protection statutes and/or state common law. Plaintiffs generally seek damages, treble damages, disgorgement of profits, restitution, injunctive relief and attorneys’ fees. In March 2019, direct and indirect purchaser plaintiffs filed motions for class certification, which remain pending. Expert discovery is ongoing.

Beginning in February 2009, the FTC and certain private plaintiffs filed suit against our subsidiary Par Pharmaceutical Companies, Inc. (since June 2016, EGHI) and other pharmaceutical companies alleging violations of antitrust law arising out of their settlement of certain patent litigation concerning the generic version of AndroGel^®. Generally, the complaints seek damages, treble damages, equitable relief and attorneys’ fees and costs. The cases have been consolidated and/or coordinated for pretrial proceedings in a federal MDL pending in the U.S. District Court for the Northern District of Georgia (MDL No. 2084). In September 2012, the MDL court granted summary judgment to defendants on plaintiffs’ claims of sham litigation. In May 2016, plaintiffs representing a putative class of indirect purchasers voluntarily dismissed their claims with prejudice. In February 2017, the FTC voluntarily dismissed its claims against EGHI with prejudice. Claims by certain alleged direct purchasers or their assignees are still pending against EGHI and other defendants. In June 2018, the MDL court granted in part and denied in part various summary judgment and evidentiary motions filed by defendants. In particular, the court rejected two of direct purchasers’ three causation theories, rejected damages claims related to AndroGel^® 1.62% and granted in part a motion seeking to exclude part of plaintiffs’ proposed manufacturing expert’s opinions. The motions were denied in all other respects. In July 2018, the court denied certain plaintiffs’ motion for certification of a direct purchaser class. The MDL court has scheduled a trial for February 2020. In August 2019, following the MDL court’s denial of class certification, several alleged direct purchasers filed a separate suit in the U.S. District Court for the Eastern District of Pennsylvania asserting claims substantially similar to those asserted in the MDL, as well as additional claims against other defendants relating to other patent settlement agreements. In September 2019, the defendants filed a motion to transfer venue to the Northern District of Georgia to permit coordination with the MDL. That motion remains pending.

Beginning in May 2018, multiple complaints were filed in the U.S. District Court for the Southern District of New York against PPI, EPI and/or us, as well as other pharmaceutical companies alleging violations of antitrust law arising out of their settlement of certain patent litigation concerning the generic version of Exforge^® (amlodipine/valsartan). Some cases were filed on behalf of putative classes of direct and indirect purchasers; others are non-class action suits. The various complaints assert claims under Sections 1 and 2 of the Sherman Act, state antitrust and consumer protection statutes and/or state common law. Plaintiffs generally seek damages, treble damages, equitable relief and attorneys’ fees and costs. In September 2018, the putative class plaintiffs stipulated to the dismissal without prejudice of their claims against EPI and us, and the retailer plaintiffs later did the same. PPI filed a partial motion to dismiss certain claims in September 2018, which was granted in August 2019. The case is currently in discovery.

Beginning in February 2018, several alleged indirect purchasers filed proposed class actions against our subsidiary PPI and other pharmaceutical companies alleging violations of antitrust law arising out of their settlement of certain patent litigation concerning the generic version of Zetia^®(ezetimibe). The various complaints assert claims under Sections 1 and 2 of the Sherman Act, state antitrust and consumer protection statutes and/or state common law. Plaintiffs generally seek injunctive relief, damages, treble damages, attorneys’ fees and costs. In June 2018, these and other related cases, including proposed direct purchaser class actions in which PPI was not named as a defendant, were consolidated and/or coordinated for pretrial proceedings in a federal MDL pending in the U.S. District Court for the Eastern District of Virginia (MDL No. 2836). In September 2018, the indirect purchaser plaintiffs dismissed their claims against PPI without prejudice. In May 2019, the direct purchaser plaintiffs filed a motion seeking leave of court to file an amended consolidated class complaint adding PPI as a defendant in the direct purchaser actions, which leave was granted in June 2019; certain retailer plaintiffs filed a similar motion, which was granted in July 2019. In July 2019, PPI entered into settlement agreements with both the direct purchaser plaintiffs and the retailer plaintiffs. The direct purchaser settlement is subject to court approval. The settlement agreements involve no admission of liability and no monetary payment.

Beginning in August 2019, multiple complaints were filed in the U.S. District Court for the Southern District of New York against PPI and other pharmaceutical companies alleging violations of antitrust law arising out the settlement of certain patent litigation concerning generic versions of Seroquel XR^®(extended release quetiapine fumarate). The claims against PPI are based on allegations that PPI entered into an exclusive acquisition and license agreement with Handa Pharmaceuticals, LLC (Handa) in 2012 pursuant to which Handa assigned to PPI certain rights under a prior settlement agreement between Handa and AstraZeneca resolving certain patent litigation. Some cases were filed on behalf of putative classes of direct and indirect purchasers; others are non-class action suits. The various complaints assert claims under Sections 1 and 2 of the Sherman Act, state antitrust and consumer protection statutes and/or state common law. Plaintiffs generally seek damages, treble damages, equitable relief and attorneys’ fees and costs. In October 2019, the defendants filed various motions to dismiss and, in the alternative, moved to transfer the litigation to the U.S. District Court for the District of Delaware.

In November 2014, EPI received a CID from Florida’s Office of the Attorney General seeking documents and other information concerning EPI’s agreement with Actavis settling the LIDODERM^® patent litigation, as well as information concerning marketing and sales of LIDODERM^®. EPI and/or EHSI later received similar CIDs from Alaska and South Carolina. In May 2019, we and EPI entered into a settlement with the state of California resolving potential antitrust and consumer protection claims concerning EPI’s agreement with Actavis settling the LIDODERM^® patent litigation, and in July 2019, we and EPI entered into a similar settlement with 18 additional states: Alabama, Arkansas, Florida, Hawaii, Idaho, Illinois, Indiana, Iowa, Maryland, Minnesota, Mississippi, Missouri, Ohio, Oklahoma, Utah, Virginia, Washington and Wisconsin. The settlements involve no admission of liability, and payments provided for in the settlements are not material to the Company. As part of the settlements, we agreed to certain covenants relating to the future settlement of patent infringement litigation through February 2027. These covenants, which are consistent with Endo’s current practices in settling patent infringement cases and consistent with the settlement agreement we reached with the Federal Trade Commission in January 2017, include a prohibition on patent settlement agreements that prevent the marketing of authorized generic products or that involve certain payments to generic manufacturers. The covenants are included in stipulated orders subject to approval by the U.S. District Court for the Northern District of California. The court approved the stipulated order relating to the California settlement in June 2019; with respect to the other settlement, the court approved the stipulated order in August 2019.

To the extent unresolved, we will continue to vigorously defend the foregoing matters and to explore other options as appropriate in our best interests. Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred. Adjustments to our overall liability accrual may be required in the future, which could have a material adverse effect on our business, financial condition, results of operations and cash flows.

In February 2015, EGHI and affiliates received a CID from the Office of the Attorney General for the state of Alaska seeking production of certain documents and information regarding EGHI’s settlement of AndroGel^® patent litigation as well as documents produced in the aforementioned litigation filed by the FTC. Also in February 2015, EHSI received a CID from Alaska’s Office of the Attorney General seeking production of certain documents and information concerning agreements with Actavis and Impax settling OPANA^® ER patent litigation. We are cooperating with the investigations.

In July 2019, EPI received a CID from the Federal Trade Commission seeking production of certain documents and information regarding oxymorphone ER and EPI’s settlement of a contract dispute with Impax Laboratories (now Amneal Pharmaceuticals) in August 2017. We are cooperating with the investigation.

Similar investigations may be brought by others or the foregoing matters may be expanded or result in litigation. We are unable to predict the outcome of these matters or to estimate the possible range of any additional losses that could be incurred. Adjustments to our overall liability accrual may be required in the future, which could have a material adverse effect on our business, financial condition, results of operations and cash flows.

Securities Litigation

In February 2017, a putative class action entitled Public Employees’ Retirement System of Mississippi v. Endo International plc was filed in the Court of Common Pleas of Chester County, Pennsylvania by an institutional purchaser of shares in our June 2, 2015 public offering. The complaint alleged violations of Sections 11, 12(a)(2) and 15 of the Securities Act of 1933 against Endo, certain of its current and former directors and officers, and the underwriters who participated in the offering, based on certain disclosures about Endo’s generics business. In June 2019, the parties entered into a settlement, subject to court approval, which provides for a $50 million payment to the investor class in exchange for a release of their claims. The court preliminarily approved the settlement in July 2019; a final approval hearing is set for November 2019. As a result of the settlement, during the first quarter of 2019, the Company recorded an increase of approximately $50 million to its accrual for loss contingencies. As the Company’s insurers agreed to fund the settlement, the Company also recorded a corresponding insurance receivable of approximately $50 million during the first quarter of 2019, which was recorded as Prepaid expenses and other current assets in the Condensed Consolidated Balance Sheets. The Company’s insurers funded the settlement during the third quarter of 2019, resulting in corresponding decreases to the Company’s accrual for loss contingencies and insurance receivable.

In April 2017, a putative class action entitled Phaedra A. Makris v. Endo International plc, Rajiv Kanishka Liyanaarchchie de Silva and Suketu P. Upadhyay was filed in the Superior Court of Justice in Ontario, Canada by an individual shareholder on behalf of herself and similarly-situated Canadian-based investors who purchased Endo’s securities between January 11 and May 5, 2016. The original statement of claim generally sought class certification, declaratory relief, damages, interest and costs based on alleged violations of the Ontario Securities Act. The original statement of claim alleged negligent misrepresentations concerning the Company’s revenues, profit margins and earnings per share; its receipt of a subpoena from the state of Connecticut regarding doxycycline hyclate, amitriptyline hydrochloride, doxazosin mesylate, methotrexate sodium and oxybutynin chloride; and the erosion of the Company’s U.S. generic pharmaceuticals business. In January 2019, plaintiff amended her statement of claim to add a claim on behalf of herself and similarly-situated Canadian investors who purchased Endo’s securities between January 11, 2016 and June 8, 2017. This additional claim is based on the Company’s decision to remove reformulated OPANA^® ER from the market.

In August 2017, an alleged individual shareholder filed a putative class action entitled Bier v. Endo International plc, et al. in the U.S. District Court for the Eastern District of Pennsylvania. The original complaint alleged violations of Sections 10(b) and 20(a) of the Exchange Act against Endo and four current and former directors and officers, based on the Company’s decision to remove reformulated OPANA^® ER from the market. In December 2017, the court appointed SEB Investment Management AB lead plaintiff in the action. In February 2018, the lead plaintiff filed an amended complaint, which added claims alleging violations of Sections 11 and 15 of the Securities Act in connection with the June 2015 offering. The amended complaint named the Company, EHSI and 20 current and former directors, officers and employees of Endo as defendants. In December 2018, the court dismissed the plaintiff’s claims against four individual defendants. In May 2019, the parties stipulated to the dismissal of the claims brought pursuant to Sections 11 and 15 of the Securities Act, which the court accordingly dismissed without prejudice. In August 2019, the parties entered into a settlement, subject to court approval, which provides for a payment of $82.5 million to the investor class in exchange for a release of their claims. The court preliminarily approved the settlement in September 2019 and scheduled a final approval hearing for December 2019. As a result of the settlement, during the second quarter of 2019, the Company recorded an increase of approximately $82.5 million to its accrual for loss contingencies. As the Company’s insurers agreed to fund the settlement, the Company also recorded a corresponding insurance receivable of approximately $82.5 million during the second quarter of 2019, which was recorded as Prepaid expenses and other current assets in the Condensed Consolidated Balance Sheets. The Company’s insurers funded $20.0 million of the settlement amount during the third quarter of 2019, resulting in corresponding decreases to the Company’s accrual for loss contingencies and insurance receivable. The Company’s insurers funded the remainder in October 2019.

In November 2017, a putative class action entitled Pelletier v. Endo International plc, Rajiv Kanishka Liyanaarchchie De Silva, Suketu P. Upadhyay and Paul V. Campanelli was filed in the U.S. District Court for the Eastern District of Pennsylvania by an individual shareholder on behalf of himself and all similarly situated shareholders. The lawsuit alleges violations of Section 10(b) and 20(a) of the Exchange Act relating to the pricing of various generic pharmaceutical products. In June 2018, the court appointed Park Employees’ Annuity and Benefit Fund of Chicago lead plaintiff in the action. In August 2018, the lead plaintiff filed an amended complaint. In September 2018, the defendants moved to dismiss the amended complaint. That motion remains pending.

VASOSTRICT^®Related Matters

In July 2016, Fresenius Kabi USA, LLC (Fresenius) filed a complaint against PPCI and its affiliate Par Sterile Products, LLC (PSP) in the U.S. District Court for the District of New Jersey alleging that PPCI and its affiliate engaged in an anticompetitive scheme to exclude competition for PPCI’s VASOSTRICT^®, a vasopressin-based cardiopulmonary drug. The complaint alleges violations of Sections 1 and 2 of the Sherman Antitrust Act, as well as state antitrust and common law, based on assertions that PPCI and its affiliate entered into exclusive supply agreements with one or more active pharmaceutical ingredient (API) manufacturers and that, as a result, Fresenius could not obtain vasopressin API in order to file an Abbreviated New Drug Application (ANDA) to obtain U.S. Food and Drug Administration (FDA) approval for its own vasopressin product. Fresenius seeks actual, treble and punitive damages, attorneys’ fees and costs and injunctive relief. The parties filed cross-motions for summary judgment in July 2019; those motions remain pending.

In August 2017, our subsidiaries PPI and PSP filed a complaint for actual, exemplary and punitive damages, injunctive relief and other relief against QuVa Pharma, Inc. (QuVa), Stuart Hinchen, Peter Jenkins and Mike Rutkowski in the U.S. District Court for the District of New Jersey. The complaint alleges misappropriation in violation of the federal Defend Trade Secrets Act, New Jersey’s Trade Secrets Act and New Jersey common law, as well as unfair competition, breach of contract, breach of fiduciary duty, breach of the duty of loyalty, tortious interference with contractual relations and breach of the duty of confidence in connection with VASOSTRICT^®. In November 2017, we filed a motion for preliminary injunction seeking various forms of relief. In January 2018, we filed a first amended complaint adding four former employees and one former consultant of PSP as defendants and numerous causes of action against some or all of those individuals, including misappropriation under the federal Defend Trade Secrets Act, New Jersey’s Trade Secrets Act and New Jersey common law, as well as breach of contract, breach of the duty of loyalty and breach of the duty of confidence. In March 2018, the court granted in part our motion for preliminary injunction and enjoined QuVa from marketing and releasing its planned vasopressin product through the conclusion of trial. We subsequently deposited a bond to the court’s interest-bearing account to secure the preliminary injunction. Defendants filed a motion asking the court to reconsider the bond amount, which the court denied. Also in March 2018, QuVa and seven of the individual defendants filed a motion to dismiss the New Jersey common law claims, four of the individual defendants filed a motion to dismiss for lack of personal jurisdiction and one of the individuals filed a motion to dismiss the breach of contract claim. In April 2018, another individual defendant filed a motion to dismiss asserting numerous arguments, including lack of personal jurisdiction, improper venue and choice of law. Discovery began in May 2018. Also in May 2018, defendants filed a notice of appeal to the Third Circuit Court of Appeals indicating intent to appeal the court’s preliminary injunction. The parties completed appellate briefing in January 2019. Also in January 2019, the court denied all four of defendants’ pending motions to dismiss. In February 2019, the defendants filed their answers and affirmative defenses and certain defendants also filed counterclaims for defamation, tortious interference with contract, tortious interference with prospective business relations and witness interference. The counterclaims seek actual, exemplary and punitive damages and other relief. In March 2019, we filed a motion to dismiss all of the defendants’ counterclaims. This motion is still pending. In April 2019, the Third Circuit Court of Appeals affirmed the court’s preliminary injunction but remanded for additional fact-finding concerning the duration of the preliminary injunction and, if needed, consideration of the additional trade secrets raised in our motion for preliminary injunction but not addressed by the preliminary injunction order. The parties completed remand briefing in June 2019 and, following oral argument in July 2019, the court took the issue under submission. In September 2019, following the decision in the Athenex matter upholding the FDA’s determination that there is no clinical need for outsourcing facilities to compound drugs using bulk vasopressin (described below), the parties submitted a proposed consent order to the district court agreeing to a lifting of the preliminary injunction against QuVa but reserving PPI and PSP’s right to seek return or reduction of the bond. The court has not yet ruled on PPI and PSP’s request for return or reduction of the bond.

In October 2017, Endo Par Innovation Company, LLC (EPIC) and PSP filed a complaint in the U.S. District Court for the District of Columbia challenging the legality of the FDA’s Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act (January 2017) with respect to the listing of vasopressin in Category 1 of the Interim Policy. The complaint contends that the Interim Policy is unlawful because it is inconsistent with the Federal Food, Drug, and Cosmetic Act, including, but not limited to, Section 503B of that Act. The complaint sought (i) a declaration that FDA’s Interim Policy and its listing of vasopressin in Category 1 of the Interim Policy are unlawful and (ii) an order enjoining and vacating the Interim Policy and the FDA’s listing of vasopressin in Category 1 of the Interim Policy. In January 2018, EPIC and PSP agreed to a temporary 60-day stay of the litigation in light of the FDA’s announcement that forthcoming guidance would address the concerns set forth in the Company’s complaint. In March 2018, the FDA released new draft guidance for industry entitled “Evaluation of Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act.” Shortly thereafter, the parties agreed to extend the temporary stay for an additional 180 days. In August 2018, before the 180-day stay period expired, Athenex Pharma Solutions, LLC and Athenex Pharmaceutical Division, LLC announced they had commenced bulk compounding of vasopressin, and moved to intervene in EPIC and PSP’s case against the FDA. Later that month, EPIC and PSP invoked their ability to terminate the stay and filed a motion for preliminary injunction. Before responding to the motion for preliminary injunction, the FDA issued a notice containing a proposed finding that there is no clinical need to bulk compound vasopressin under Section 503B in August 2018. In September 2018, the FDA advised EPIC and PSP that it would agree to use its best efforts to finalize the vasopressin clinical need rulemaking by December 31, 2018, if the case were again stayed. EPIC and PSP agreed to the requested stay. In December 2018, the appropriations act that had been funding the DOJ and components of the FDA expired, resulting in a lapse of appropriations; therefore, the FDA moved the court for a further stay of the case until appropriations were restored. The court granted the motion in January 2019, ordering the FDA to file a notification with the court within three business days of DOJ operations resuming. After government appropriations were restored, the FDA advised that it would use its best efforts to finalize the vasopressin clinical need determination by March 15, 2019. The FDA finalized the vasopressin clinical need determination in March 2019, finding that because of VASOSTRICT^®’s availability, there is no clinical need for outsourcing facilities to compound drugs using bulk vasopressin. That same day, Athenex, Inc., Athenex Pharma Solutions, LLC, and Athenex Pharmaceutical Division, LLC filed a complaint in the U.S. District Court for the District of Columbia, challenging the FDA’s clinical need determination for vasopressin. EPIC and PSP intervened as defendants in the action. The parties and the court agreed to an expedited summary judgment briefing, and a hearing on cross-motions for summary judgment was held in April 2019. In August 2019, the court granted defendants’ motion for summary judgment and denied plaintiffs’ motion for summary judgment. The court subsequently denied plaintiffs’ motion for a stay or injunction of the court’s order pending appeal to the United States Court of Appeals for the District of Columbia Circuit (D.C. Circuit). Plaintiffs then withdrew their appeal and the D.C. Circuit dismissed the case. In September 2019, all parties also stipulated to the dismissal without prejudice of EPIC and PSP’s suit against the FDA, and that case was closed.

In August 2018, Athenex filed a declaratory judgment action in the U.S. District Court for the Western District of New York, a case styled Athenex v. Par, alleging non-infringement and/or invalidity of the patents the Company has listed in the Orange Book in view of VASOSTRICT^®. The Company moved to dismiss Athenex’s case on multiple grounds in October 2018, which motion was opposed by Athenex in December 2018. The Company responded to this opposition in December 2018. In July 2019, the court granted our motion and dismissed Athenex’s declaratory judgment action and the time for Athenex to appeal has expired. This matter is now closed.

In April 2018, PSP and PPI received a notice letter from Eagle Pharmaceuticals, Inc. (Eagle) advising of the filing by such company of an ANDA for a generic version of VASOSTRICT^® (vasopressin IV solution (infusion)) 20 units/ml. In May 2018, PSP and PPI received a second notice letter from Eagle advising of the same filing, but adding an additional patent. The Paragraph IV notices refer to U.S. Patent Nos. 9,375,478; 9,687,526; 9,744,209; 9,744,239; 9,750,785 and 9,937,223, which variously cover either vasopressin-containing pharmaceutical compositions or methods of using a vasopressin-containing dosage form to increase blood pressure in humans. In May 2018, PPI, PSP and EPIC filed a lawsuit against Eagle in the U.S. District Court for the District of Delaware within the 45-day deadline to invoke a 30-month stay of FDA approval pursuant to the Hatch-Waxman legislative scheme. In August 2018, Eagle filed an answer and a counterclaim for non-infringement and invalidity of asserted patents. A claim construction hearing was held in May 2019 and a bench trial is scheduled for May 2020.

In September 2018, PSP and PPI received a notice letter from Sandoz Inc. (Sandoz) advising of the filing by such company of an ANDA for a generic version of VASOSTRICT^® (vasopressin IV solution (infusion)) 200 units/10 ml. In October 2018, PPI, PSP and EPIC filed a lawsuit against Sandoz in the U.S. District Court for the District of New Jersey within the 45-day deadline to invoke a 30-month stay of FDA approval pursuant to the Hatch-Waxman legislative scheme. In October 2018, PSP and PPI received an additional notice letter from Sandoz advising of the filing by such company of an ANDA for a generic version of the 20 units/1 ml presentation for VASOSTRICT^®. In November 2018, the complaint was amended to add a claim for the additional notice letter, within the 45-day deadline to invoke a 30-month stay of FDA approval pursuant to the Hatch-Waxman legislative scheme.

In November 2018, PSP and PPI received a notice letter from Amphastar Pharmaceuticals, Inc. (Amphastar) advising of the filing by such company of an ANDA for a generic version of VASOSTRICT^® (vasopressin IV solution (infusion)) 20 units/1 ml. In December 2018, PPI, PSP and EPIC filed a lawsuit against Amphastar in the U.S. District Court for the District of Delaware within the 45-day deadline to invoke a 30-month stay of FDA approval pursuant to the Hatch-Waxman legislative scheme. A trial is scheduled for January 2021.

In March 2019, PSP and PPI received a notice letter from Amneal Pharmaceuticals LLC (Amneal) advising of the filing by such company of an ANDA for a generic version of VASOSTRICT^® (vasopressin IV solution (infusion)) 20 units/1 ml and 200 units/10 ml. In April 2019, PPI, PSP and EPIC filed a lawsuit against Amneal in the U.S. District Court for the District of Delaware within the 45-day deadline to invoke a 30-month stay of FDA approval pursuant to the Hatch-Waxman legislative scheme. A trial is scheduled for January 2021.

In June 2019, PSP and PPI received a notice letter from American Regent advising of the filing by such company of an ANDA for a generic version of VASOSTRICT^® (vasopressin IV solution (infusion)) 20 units/1 ml. In August 2019, PPI, PSP and EPIC filed a lawsuit against American Regent in the U.S. District Court for the District of Delaware within the 45-day deadline to invoke a 30-month stay of FDA approval pursuant to the Hatch-Waxman legislative scheme. A trial is scheduled for January 2021.

In September 2019, PSP and PPI received a notice letter from Fresenius Kabi advising of the filing by such company of an ANDA for a generic version of VASOSTRICT^® (vasopressin IV solution (infusion)) 20 units/1 ml and 200 units/10 ml. In October 2019, PPI, PSP and EPIC filed a lawsuit against Fresenius Kabi in the U.S. District Court for the District of Delaware within the 45-day deadline to invoke a 30-month stay of FDA approval pursuant to the Hatch-Waxman legislative scheme.

The Company’s accrual for loss contingencies includes, among other things, an estimated accrual for certain VASOSTRICT^®-related matters. We will continue to vigorously defend or prosecute the foregoing matters as appropriate, to protect our intellectual property rights, to pursue all available legal and regulatory avenues and to explore other options as appropriate in our best interests. Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any additional losses that could be incurred. Adjustments to our overall liability accrual may be required in the future, which could have a material adverse effect on our business, financial condition, results of operations and cash flows.

Other Proceedings and Investigations

Proceedings similar to those described above may also be brought in the future. Additionally, we are involved in, or have been involved in, arbitrations or various other proceedings that arise from the normal course of our business. We cannot predict the timing or outcome of these other proceedings. Currently, neither we nor our subsidiaries are involved in any other proceedings that we expect to have a material effect on our business, financial condition, results of operations and cash flows.

Shareholders' Deficit

9 Months Ended

Sep. 30, 2019

Equity [Abstract]

SHAREHOLDERS' DEFICIT

NOTE 15. SHAREHOLDERS' DEFICIT

The following table presents a reconciliation of the beginning and ending balances in Total shareholders' deficit for the three and nine months ended September 30, 2019 (in thousands):



	Euro Deferred Shares			Ordinary Shares		Additional Paid-in Capital			Accumulated Deficit			Accumulated Other Comprehensive Loss			Total Shareholders' Deficit
BALANCE, DECEMBER 31, 2018, PRIOR TO THE ADOPTION OF ASC 842 (1)	$	46		$	22	$	8,855,810		$	(9,124,932	)	$	(229,229	)	$	(498,283	)
Effect of adopting ASC 842 (1)	—			—		—			(4,646		)	—			(4,646		)
BALANCE, JANUARY 1, 2019	$	46		$	22	$	8,855,810		$	(9,129,578	)	$	(229,229	)	$	(502,929	)
Net loss	—			—		—			(18,573		)	—			(18,573		)
Other comprehensive income	—			—		—			—			4,730			4,730
Compensation related to share-based awards	—			—		24,733			—			—			24,733
Exercise of options	—			—		4			—			—			4
Tax withholding for restricted shares	—			—		(2,414		)	—			—			(2,414		)
Other	(1		)	—		—			—			—			(1		)
BALANCE, MARCH 31, 2019	$	45		$	22	$	8,878,133		$	(9,148,151	)	$	(224,499	)	$	(494,450	)
Net loss	—			—		—			(106,005		)	—			(106,005		)
Other comprehensive income	—			—		—			—			4,395			4,395
Compensation related to share-based awards	—			—		12,600			—			—			12,600
Tax withholding for restricted shares	—			—		(7,013		)	—			—			(7,013		)
Other	—			1		—			—			—			1
BALANCE, JUNE 30, 2019	$	45		$	23	$	8,883,720		$	(9,254,156	)	$	(220,104	)	$	(590,472	)
Net loss	—			—		—			(79,415		)	—			(79,415		)
Other comprehensive loss	—			—		—			—			(2,515		)	(2,515		)
Compensation related to share-based awards	—			—		11,576			—			—			11,576
Tax withholding for restricted shares	—			—		(650		)	—			—			(650		)
Other	(1		)	—		—			—			—			(1		)
BALANCE, SEPTEMBER 30, 2019	$	44		$	23	$	8,894,646		$	(9,333,571	)	$	(222,619	)	$	(661,477	)

__________


(1)	Refer to Note 2. Summary of Significant Accounting Policies for further description of ASC 842.

The following table presents a reconciliation of the beginning and ending balances in Total shareholders' equity (deficit) for the three and nine months ended September 30, 2018 (in thousands):



	Euro Deferred Shares			Ordinary Shares		Additional Paid-in Capital			Accumulated Deficit			Accumulated Other Comprehensive Loss			Total Shareholders' Equity (Deficit)
BALANCE, DECEMBER 31, 2017, PRIOR TO THE ADOPTION OF ASC 606 (1)	$	48		$	22	$	8,791,170		$	(8,096,539	)	$	(209,821	)	$	484,880
Effect of adopting ASC 606 (1)	—			—		—			3,076			—			3,076
BALANCE, JANUARY 1, 2018	$	48		$	22	$	8,791,170		$	(8,093,463	)	$	(209,821	)	$	487,956
Net loss	—			—		—			(505,489		)	—			(505,489		)
Other comprehensive loss	—			—		—			—			(5,797		)	(5,797		)
Compensation related to share-based awards	—			—		17,890			—			—			17,890
Tax withholding for restricted shares	—			—		(1,642		)	—			—			(1,642		)
Other	1			—		(12		)	—			—			(11		)
BALANCE, MARCH 31, 2018	$	49		$	22	$	8,807,406		$	(8,598,952	)	$	(215,618	)	$	(7,093	)
Net loss	—			—		—			(60,867		)	—			(60,867		)
Other comprehensive loss	—			—		—			—			(5,971		)	(5,971		)
Compensation related to share-based awards	—			—		12,096			—			—			12,096
Tax withholding for restricted shares	—			—		(234		)	—			—			(234		)
Other	(2		)	—		(6		)	—			—			(8		)
BALANCE, JUNE 30, 2018	$	47		$	22	$	8,819,262		$	(8,659,819	)	$	(221,589	)	$	(62,077	)
Net loss	—			—		—			(173,205		)	—			(173,205		)
Other comprehensive income	—			—		—			—			4,735			4,735
Compensation related to share-based awards	—			—		13,736			—			—			13,736
Exercise of options	—			—		473			—			—			473
Tax withholding for restricted shares	—			—		(3,206		)	—			—			(3,206		)
Other	(1		)	—		86			—			—			85
BALANCE, SEPTEMBER 30, 2018	$	46		$	22	$	8,830,351		$	(8,833,024	)	$	(216,854	)	$	(219,459	)

__________

(1)

The Company adopted ASC 606 on January 1, 2018 using the modified retrospective method for all revenue-generating contracts, including modifications thereto, that were not completed contracts at the date of adoption. As a result of adopting ASC 606, the Company recorded a net decrease of $3.1 million to its accumulated deficit at January 1, 2018, representing the cumulative impact of adopting ASC 606.

Share-Based Compensation

The Company recognized share-based compensation expense of $11.6 million and $13.7 million during the three months ended September 30, 2019 and 2018, respectively, and $48.9 million and $43.7 million during the nine months ended September 30, 2019 and 2018, respectively. As of September 30, 2019, the total remaining unrecognized compensation cost related to non-vested share-based compensation awards amounted to $61.6 million.

As of September 30, 2019, the weighted average remaining requisite service period for non-vested stock options was 1.1 years and for non-vested restricted stock units was 1.8 years.

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

Lease Accounting

The Company adopted Accounting Standards Codification Topic 842, Leases (ASC 842) on January 1, 2019. For further discussion of the adoption, refer to the “Recent Accounting Pronouncements Adopted or Otherwise Effective as of September 30, 2019” section below. ASC 842 applies to a number of arrangements to which the Company is party.

For each lease, the Company must then determine the lease term, the present value of lease payments and the classification of the lease as either an operating or finance lease.

The present value of lease payments is calculated based on:

•

Cloud Computing Arrangements

The Company may from time to time incur costs in connection with hosting arrangements that are service contracts. Subsequent to the Company’s January 1, 2019 adoption of Accounting Standards Update (ASU) No. 2018-15, “Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract” (ASU 2018-15), which is further described below, the Company capitalizes any such implementation costs, expenses them over the terms of the respective hosting arrangements and subjects them to impairment testing consistent with other long-lived assets.

Recent Accounting Pronouncements

Recently Issued Accounting Pronouncements Not Yet Adopted as of September 30, 2019

Recent Accounting Pronouncements Adopted or Otherwise Effective as of September 30, 2019

Discontinued Operations (Tables)

9 Months Ended

Sep. 30, 2019

Discontinued Operations and Disposal Groups [Abstract]

Schedule of disposal groups, including discontinued operations, income statement, balance sheet and additional disclosures

The following table provides the operating results of Astora Discontinued operations, net of tax, for the three and nine months ended September 30, 2019 and 2018 (in thousands):



	Three Months Ended September 30,						Nine Months Ended September 30,
	2019			2018			2019			2018
Litigation-related and other contingencies, net	$	30,000		$	19,000		$	30,400		$	19,000
Loss from discontinued operations before income taxes	$	(37,984	)	$	(27,134	)	$	(51,898	)	$	(43,273	)
Income tax benefit	$	—		$	—		$	—		$	—
Discontinued operations, net of tax	$	(37,984	)	$	(27,134	)	$	(51,898	)	$	(43,273	)

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760

+ Details

Segment Results (Tables)

9 Months Ended

Sep. 30, 2019

Segment Reporting [Abstract]

Schedule of reportable segments information

The following represents selected information for the Company’s reportable segments for the three and nine months ended September 30, 2019 and 2018 (in thousands):



	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Net revenues from external customers:
Branded Pharmaceuticals	$	217,313	$	220,100	$	629,851	$	632,972
Sterile Injectables	263,635		237,150		777,963		670,847
Generic Pharmaceuticals	218,012		257,969		654,322		748,445
International Pharmaceuticals (1)	30,466		30,247		87,428		108,425
Total net revenues from external customers	$	729,426	$	745,466	$	2,149,564	$	2,160,689
Adjusted income from continuing operations before income tax:
Branded Pharmaceuticals	$	91,444	$	84,891	$	253,417	$	262,454
Sterile Injectables	197,974		170,329		566,345		513,082
Generic Pharmaceuticals	29,433		82,555		128,738		247,137
International Pharmaceuticals	11,511		13,377		35,053		45,594
Total segment adjusted income from continuing operations before income tax	$	330,362	$	351,152	$	983,553	$	1,068,267

__________

(1)

Revenues generated by our International Pharmaceuticals segment are primarily attributable to external customers located in Canada.



	Three Months Ended September 30,						Nine Months Ended September 30,
	2019			2018			2019			2018
Total consolidated loss from continuing operations before income tax	$	(24,070	)	$	(143,068	)	$	(120,363	)	$	(671,559	)
Interest expense, net	136,903			131,847			404,387			385,896
Corporate unallocated costs (1)	37,891			49,187			124,351			144,693
Amortization of intangible assets	131,932			161,275			417,949			471,662
Inventory step-up	—			71			—			261
Upfront and milestone payments to partners	1,672			4,731			4,055			43,027
Retention and separation benefits and other cost reduction initiatives (2)	11,023			4,001			15,172			82,141
Certain litigation-related and other contingencies, net (3)	(14,414		)	(1,750		)	(4,093		)	15,370
Asset impairment charges (4)	4,766			142,217			258,652			613,400
Acquisition-related and integration items (5)	16,025			1,288			(26,983		)	13,284
Gain on extinguishment of debt	—			—			(119,828		)	—
Foreign currency impact related to the remeasurement of intercompany debt instruments	(922		)	1,528			2,874			(1,560		)
Other, net (6)	29,556			(175		)	27,380			(28,348		)
Total segment adjusted income from continuing operations before income tax	$	330,362		$	351,152		$	983,553		$	1,068,267

__________


(1)	Amounts include certain corporate overhead costs, such as headcount, facility and corporate litigation expenses and certain other income and expenses.

(2)


(3)	Amounts include adjustments to our accruals for litigation-related settlement charges and certain settlement proceeds related to suits filed by our subsidiaries. Our material legal proceedings and other contingent matters are described in more detail in Note 13. Commitments and Contingencies.


(4)	Amounts primarily relate to charges to impair goodwill and intangible assets as further described in Note 9. Goodwill and Other Intangibles.


(5)	Amounts primarily relate to changes in the fair value of contingent consideration.

(6)

Disaggregation of revenue



	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Branded Pharmaceuticals:
Specialty Products:
XIAFLEX®	$	82,756	$	64,214	$	226,118	$	184,855
SUPPRELIN® LA	20,772		20,408		66,542		60,948
Other Specialty (1)	28,470		27,614		78,397		69,226
Total Specialty Products	$	131,998	$	112,236	$	371,057	$	315,029
Established Products:
PERCOCET®	$	28,561	$	30,730	$	88,199	$	93,539
TESTOPEL®	13,236		15,962		40,830		44,976
Other Established (2)	43,518		61,172		129,765		179,428
Total Established Products	$	85,315	$	107,864	$	258,794	$	317,943
Total Branded Pharmaceuticals (3)	$	217,313	$	220,100	$	629,851	$	632,972
Sterile Injectables:
VASOSTRICT®	$	129,691	$	112,333	$	384,854	$	332,387
ADRENALIN®	40,311		35,460		133,468		101,858
APLISOL®	28,085		15,992		55,996		49,064
Ertapenem for injection	21,853		25,798		79,619		25,798
Other Sterile Injectables (4)	43,695		47,567		124,026		161,740
Total Sterile Injectables (3)	$	263,635	$	237,150	$	777,963	$	670,847
Total Generic Pharmaceuticals (5)	$	218,012	$	257,969	$	654,322	$	748,445
Total International Pharmaceuticals (6)	$	30,466	$	30,247	$	87,428	$	108,425
Total revenues, net	$	729,426	$	745,466	$	2,149,564	$	2,160,689

__________


(1)	Products included within Other Specialty are NASCOBAL^®Nasal Spray and AVEED^®. Beginning with our first-quarter 2019 reporting, TESTOPEL^®, which was previously included in Other Specialty, has been reclassified and is now included in the Established Products portfolio for all periods presented.


(2)	Products included within Other Established include, but are not limited to, LIDODERM^®, VOLTAREN^® Gel, EDEX^®, FORTESTA^® Gel and TESTIM^®, including the authorized generics of FORTESTA^® Gel and TESTIM^®.


(3)	Individual products presented above represent the top two performing products in each product category for either the three or nine months ended September 30, 2019 and/or any product having revenues in excess of $25 million during any quarterly period in 2019 or 2018.


(4)	Products included within Other Sterile Injectables include ephedrine sulfate injection and others.

(5)

(6)

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2019

Fair Value Disclosures [Abstract]

Schedule of cash and cash equivalents

The following table presents current and noncurrent restricted cash and cash equivalent balances at September 30, 2019 and December 31, 2018 (in thousands):



	September 30, 2019		December 31, 2018
Restricted cash and cash equivalents—current portion (1)	$	222,491	$	305,368
Restricted cash and cash equivalents—noncurrent portion (2)	22,357		22,356
Restricted cash and cash equivalents—total (3)	$	244,848	$	327,724

__________


(1)	These amounts are reported in our Condensed Consolidated Balance Sheets as Restricted cash and cash equivalents.


(2)	These amounts are reported in our Condensed Consolidated Balance Sheets as Other assets.

(3)

Restrictions on cash and cash equivalents

The following table presents current and noncurrent restricted cash and cash equivalent balances at September 30, 2019 and December 31, 2018 (in thousands):



	September 30, 2019		December 31, 2018
Restricted cash and cash equivalents—current portion (1)	$	222,491	$	305,368
Restricted cash and cash equivalents—noncurrent portion (2)	22,357		22,356
Restricted cash and cash equivalents—total (3)	$	244,848	$	327,724

__________


(1)	These amounts are reported in our Condensed Consolidated Balance Sheets as Restricted cash and cash equivalents.


(2)	These amounts are reported in our Condensed Consolidated Balance Sheets as Other assets.

(3)

Financial assets and liabilities measured at fair value on recurring basis

The Company’s financial assets and liabilities measured at fair value on a recurring basis at September 30, 2019 and December 31, 2018 were as follows (in thousands):



	Fair Value Measurements at September 30, 2019 using:
	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Assets:
Money market funds	$	748,441	$	—	$	—	$	748,441
Liabilities:
Acquisition-related contingent consideration—current	$	—	$	—	$	20,974	$	20,974
Acquisition-related contingent consideration—noncurrent	$	—	$	—	$	38,520	$	38,520



	Fair Value Measurements at December 31, 2018 using:
	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Assets:
Money market funds	$	137,215	$	—	$	—	$	137,215
Liabilities:
Acquisition-related contingent consideration—current	$	—	$	—	$	36,514	$	36,514
Acquisition-related contingent consideration—noncurrent	$	—	$	—	$	80,189	$	80,189

Changes to liability for acquisition-related contingent consideration



	Three Months Ended September 30,						Nine Months Ended September 30,
	2019			2018			2019			2018
Beginning of period	$	52,930		$	152,098		$	116,703		$	190,442
Amounts settled	(9,376		)	(24,564		)	(30,541		)	(73,298		)
Changes in fair value recorded in earnings	16,025			769			(26,983		)	11,731
Effect of currency translation	(85		)	167			315			(405		)
End of period	$	59,494		$	128,470		$	59,494		$	128,470

The following table presents changes to the Company’s liability for acquisition-related contingent consideration during the nine months ended September 30, 2019 by acquisition (in thousands):



	Balance as of December 31, 2018		Changes in Fair Value Recorded in Earnings			Amounts Settled and Other			Balance as of September 30, 2019
Auxilium acquisition	$	14,157	$	1,086		$	(388	)	$	14,855
Lehigh Valley Technologies, Inc. acquisitions	34,700		10,566			(14,466		)	30,800
VOLTAREN® Gel acquisition (1)	56,240		(37,395		)	(14,601		)	4,244
Other	11,606		(1,240		)	(771		)	9,595
Total	$	116,703	$	(26,983	)	$	(30,226	)	$	59,494

__________

(1)

The change in fair value recorded in earnings includes the impact of certain competitive events occurring during the nine months ended September 30, 2019.

Summary of nonrecurring fair value measurements

The Company’s financial assets and liabilities measured at fair value on a nonrecurring basis during the nine months ended September 30, 2019 were as follows (in thousands):



	Fair Value Measurements during the Nine Months Ended September 30, 2019 (1) using:						Total Expense for the Nine Months Ended September 30, 2019
	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Expense for the Nine Months Ended September 30, 2019
Assets:
Intangible assets, excluding goodwill (Note 9)	$	—	$	—	$	41,839	$	(104,660	)
Certain property, plant and equipment	—		—		—		(2,884		)
Total	$	—	$	—	$	41,839	$	(107,544	)

__________

(1)

The fair value amounts are presented as of the date of the fair value measurement as these assets are not measured at fair value on a recurring basis. Such measurements generally occur in connection with our quarter-end financial reporting close procedures.

Leases (Tables)

9 Months Ended

Sep. 30, 2019

Leases [Abstract]

Assets and liabilities, lessee

The following table presents information about the Company's ROU assets and lease liabilities at September 30, 2019 (in thousands):



	Condensed Consolidated Balance Sheets Line Items	September 30, 2019
ROU assets:
Operating lease ROU assets	Operating lease assets	$	53,839
Finance lease ROU assets	Property, plant and equipment, net	59,104
Total ROU assets		$	112,943
Operating lease liabilities:
Current operating lease liabilities	Current portion of operating lease liabilities	$	10,575
Noncurrent operating lease liabilities	Operating lease liabilities, less current portion	50,965
Total operating lease liabilities		$	61,540
Finance lease liabilities:
Current finance lease liabilities	Accounts payable and accrued expenses	$	5,550
Noncurrent finance lease liabilities	Other liabilities	32,768
Total finance lease liabilities		$	38,318

Lease, cost

The following table provides the weighted average remaining lease term and weighted average discount rates for our leases as of September 30, 2019:



	September 30, 2019
Weighted average remaining lease term (years), weighted based on lease liability balances:
Operating leases	6.0 years
Finance leases	9.7 years
Weighted average discount rate (percentages), weighted based on the remaining balance of lease payments:
Operating leases	5.8	%
Finance leases	5.5	%

The following table provides certain cash flow and supplemental noncash information related to our lease liabilities for the nine months ended September 30, 2019 (in thousands):



	Nine Months Ended September 30, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash payments for operating leases	$	11,200
Operating cash payments for finance leases	$	1,535
Financing cash payments for finance leases	$	7,826
Lease liabilities arising from obtaining right-of-use assets:
Operating leases	$	623
Finance leases	$	5,901

The following table presents information about lease costs and expenses and sublease income for the three and nine months ended September 30, 2019 (in thousands):



	Condensed Consolidated Statements of Operations Line Items	Three Months Ended September 30, 2019			Nine Months Ended September 30, 2019
Operating lease cost	Various (1)	$	3,510		$	10,269
Finance lease cost:
Amortization of ROU assets	Various (1)	$	2,311		$	7,096
Interest on lease liabilities	Interest expense, net	$	271		$	1,256
Other lease costs and income:
Variable lease costs (2)	Various (1)	$	2,318		$	7,185
Sublease income	Various (1)	$	(932	)	$	(2,828	)

__________


(1)	Amounts are included in the Condensed Consolidated Statements of Operations based on the function that the underlying leased asset supports. The following table presents the components of such aggregate amounts for the three and nine months ended September 30, 2019 (in thousands):



	Three Months Ended September 30, 2019		Nine Months Ended September 30, 2019
Cost of revenues	$	2,793	$	8,425
Selling, general and administrative	$	4,347	$	13,145
Research and development	$	67	$	152

(2)

Amounts represent variable lease costs incurred that were not included in the initial measurement of the lease liability, such as common area maintenance and utilities costs associated with leased real estate and certain costs associated with our automobile leases.

Lessee, operating lease, liability, maturity



	Operating Leases		Finance Leases
2019, excluding amounts already paid	$	3,740	$	1,826
2020	13,771		7,447
2021	13,996		7,594
2022	12,424		7,744
2023	10,012		7,898
Thereafter	20,549		21,881
Total future lease payments	$	74,492	$	54,390
Less: amount representing interest	12,952		16,072
Present value of future lease payments (lease liability)	$	61,540	$	38,318

Finance lease, liability, maturity



	Operating Leases		Finance Leases
2019, excluding amounts already paid	$	3,740	$	1,826
2020	13,771		7,447
2021	13,996		7,594
2022	12,424		7,744
2023	10,012		7,898
Thereafter	20,549		21,881
Total future lease payments	$	74,492	$	54,390
Less: amount representing interest	12,952		16,072
Present value of future lease payments (lease liability)	$	61,540	$	38,318

Schedule of future minimum rental payments for operating leases

The Company’s future minimum lease commitments as of December 31, 2018 under ASC 840, as reported in the Annual Report, were as follows:



	Capital Leases (1)		Operating Leases
2019	$	6,884	$	15,800
2020	6,819		14,519
2021	6,921		12,883
2022	7,072		12,454
2023	7,225		9,945
Thereafter	9,127		20,573
Total minimum lease payments	$	44,048	$	86,174
Less: Amount representing interest	4,084
Total present value of minimum payments	$	39,964
Less: Current portion of such obligations	5,845
Long-term capital lease obligations	$	34,119

__________

(1)

The Malvern, Pennsylvania headquarters lease arrangement is included under Capital Leases.

Schedule of future minimum lease payments for capital leases

The Company’s future minimum lease commitments as of December 31, 2018 under ASC 840, as reported in the Annual Report, were as follows:



	Capital Leases (1)		Operating Leases
2019	$	6,884	$	15,800
2020	6,819		14,519
2021	6,921		12,883
2022	7,072		12,454
2023	7,225		9,945
Thereafter	9,127		20,573
Total minimum lease payments	$	44,048	$	86,174
Less: Amount representing interest	4,084
Total present value of minimum payments	$	39,964
Less: Current portion of such obligations	5,845
Long-term capital lease obligations	$	34,119

__________

(1)

The Malvern, Pennsylvania headquarters lease arrangement is included under Capital Leases.

Goodwill and Other Intangibles (Tables)

9 Months Ended

Sep. 30, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of changes in the carrying amount of goodwill

Changes in the carrying amount of our goodwill for the nine months ended September 30, 2019 were as follows (in thousands):



	Branded Pharmaceuticals		Sterile Injectables		Generic Pharmaceuticals			International Pharmaceuticals		Total
Goodwill as of December 31, 2018	$	828,818	$	2,731,193	$	151,108		$	53,517	$	3,764,636
Effect of currency translation	—		—		—			1,794		1,794
Goodwill impairment charges	—		—		(151,108		)	—		(151,108		)
Goodwill as of September 30, 2019	$	828,818	$	2,731,193	$	—		$	55,311	$	3,615,322

The carrying amounts of goodwill at September 30, 2019 and December 31, 2018 are net of the following accumulated impairments (in thousands):



	Branded Pharmaceuticals		Sterile Injectables		Generic Pharmaceuticals		International Pharmaceuticals		Total
Accumulated impairment losses as of December 31, 2018	$	855,810	$	—	$	2,991,549	$	456,408	$	4,303,767
Accumulated impairment losses as of September 30, 2019	$	855,810	$	—	$	3,142,657	$	470,181	$	4,468,648

Schedule of other intangible assets

Changes in the amount of other intangible assets for the nine months ended September 30, 2019 are set forth in the table below (in thousands).



Cost basis:	Balance as of December 31, 2018			Acquisitions			Impairments			Other (1)			Effect of Currency Translation			Balance as of September 30, 2019
Indefinite-lived intangibles:
In-process research and development	$	93,900		$	—		$	—		$	—		$	—		$	93,900
Total indefinite-lived intangibles	$	93,900		$	—		$	—		$	—		$	—		$	93,900
Finite-lived intangibles:
Licenses (weighted average life of 14 years)	$	457,402		$	—		$	—		$	—		$	—		$	457,402
Tradenames	6,409			—			—			—			—			6,409
Developed technology (weighted average life of 11 years)	6,182,015			—			(104,660		)	(2,196		)	7,443			6,082,602
Total finite-lived intangibles (weighted average life of 11 years)	$	6,645,826		$	—		$	(104,660	)	$	(2,196	)	$	7,443		$	6,546,413
Total other intangibles	$	6,739,726		$	—		$	(104,660	)	$	(2,196	)	$	7,443		$	6,640,313

Accumulated amortization:	Balance as of December 31, 2018			Amortization			Impairments			Other (1)			Effect of Currency Translation			Balance as of September 30, 2019
Finite-lived intangibles:
Licenses	$	(398,182	)	$	(9,726	)	$	—		$	—		$	—		$	(407,908	)
Tradenames	(6,409		)	—			—			—			—			(6,409		)
Developed technology	(2,877,829		)	(408,223		)	—			2,196			(3,923		)	(3,287,779		)
Total other intangibles	$	(3,282,420	)	$	(417,949	)	$	—		$	2,196		$	(3,923	)	$	(3,702,096	)
Net other intangibles	$	3,457,306														$	2,938,217

__________

(1)

Other adjustments relate to the removal of certain fully amortized intangible assets.

Schedule of future amortization expense

Estimated amortization of intangibles for the five fiscal years subsequent to December 31, 2018 is as follows (in thousands):



2019	$	543,795
2020	$	457,248
2021	$	415,637
2022	$	399,886
2023	$	369,619

Schedule of intangible asset impairment charges including goodwill

During the three and nine months ended September 30, 2019 and 2018, the Company incurred the following goodwill and other intangible asset impairment charges (in thousands):



	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Goodwill impairment charges	$	—	$	—	$	151,108	$	391,000
Other intangible asset impairment charges	$	4,261	$	140,609	$	104,660	$	217,576

Debt (Tables)

9 Months Ended

Sep. 30, 2019

Debt Disclosure [Abstract]

Schedule of long-term debt instruments

The following table presents information about the Company’s total indebtedness at September 30, 2019 and December 31, 2018 (dollars in thousands):



	September 30, 2019						December 31, 2018
	Effective Interest Rate		Principal Amount		Carrying Amount		Effective Interest Rate		Principal Amount		Carrying Amount
7.25% Senior Notes due 2022	7.25	%	$	8,294	$	8,294	7.91	%	$	400,000	$	392,947
5.75% Senior Notes due 2022	5.75	%	182,479		182,479		6.04	%	700,000		694,464
5.375% Senior Notes due 2023	5.62	%	210,440		208,912		5.62	%	750,000		743,438
6.00% Senior Notes due 2023	6.28	%	1,439,840		1,426,195		6.28	%	1,635,000		1,616,817
5.875% Senior Secured Notes due 2024	6.14	%	300,000		296,497		6.14	%	300,000		296,062
6.00% Senior Notes due 2025	6.27	%	1,200,000		1,185,135		6.27	%	1,200,000		1,183,415
7.50% Senior Secured Notes due 2027	7.71	%	1,500,000		1,481,758				—		—
Term Loan B Facility Due 2024	6.59	%	3,338,162		3,309,791		7.02	%	3,363,775		3,331,276
Revolving Credit Facility	4.63	%	300,000		300,000				—		—
Total long-term debt, net			$	8,479,215	$	8,399,061			$	8,348,775	$	8,258,419
Less current portion, net			34,150		34,150				34,150		34,150
Total long-term debt, less current portion, net			$	8,445,065	$	8,364,911			$	8,314,625	$	8,224,269

Schedule of maturities of long-term debt

The following table presents the maturities on our long-term debt for each of the five fiscal years subsequent to December 31, 2018 (in thousands):



	Maturities (1)
2019	$	34,150
2020	$	34,150
2021	$	34,150
2022 (2)	$	247,723
2023	$	1,684,430

__________

(1)

(2)

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

Commitments And Contingencies (Tables)

9 Months Ended

Sep. 30, 2019

Commitments and Contingencies Disclosure [Abstract]

Changes in qualified settlement funds accounts and product liability balance

The following table presents the changes in the QSFs and mesh liability accrual balances during the nine months ended September 30, 2019 (in thousands):



	Qualified Settlement Funds			Mesh Liability Accrual
Balance as of January 1, 2019	$	299,733		$	748,606
Additional charges	—			30,000
Cash contributions to Qualified Settlement Funds	185,745			—
Cash distributions to settle disputes from Qualified Settlement Funds	(266,958		)	(266,958		)
Cash distributions to settle disputes	—			(13,334		)
Other (1)	3,125			3,256
Balance as of September 30, 2019	$	221,645		$	501,570

__________


(1)	Amounts deposited in the QSFs may earn interest, which is generally used to pay administrative costs of the fund and is reflected in the table above as an increase to the QSF and Mesh Liability Accrual balances. Any interest remaining after all claims have been paid will generally be distributed to the claimants who participated in that settlement.

- Definition

Tabular disclosure of the loss contingencies that were reported in the period or disclosed as of the balance sheet date.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14472-108349

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14453-108349

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118943654&loc=d3e12021-110248

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14394-108349

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=118943654&loc=d3e12053-110248

+ Details

Shareholders' Deficit (Tables)

9 Months Ended

Sep. 30, 2019

Equity [Abstract]

Schedule of changes in stockholders' equity

The following table presents a reconciliation of the beginning and ending balances in Total shareholders' deficit for the three and nine months ended September 30, 2019 (in thousands):



	Euro Deferred Shares			Ordinary Shares		Additional Paid-in Capital			Accumulated Deficit			Accumulated Other Comprehensive Loss			Total Shareholders' Deficit
BALANCE, DECEMBER 31, 2018, PRIOR TO THE ADOPTION OF ASC 842 (1)	$	46		$	22	$	8,855,810		$	(9,124,932	)	$	(229,229	)	$	(498,283	)
Effect of adopting ASC 842 (1)	—			—		—			(4,646		)	—			(4,646		)
BALANCE, JANUARY 1, 2019	$	46		$	22	$	8,855,810		$	(9,129,578	)	$	(229,229	)	$	(502,929	)
Net loss	—			—		—			(18,573		)	—			(18,573		)
Other comprehensive income	—			—		—			—			4,730			4,730
Compensation related to share-based awards	—			—		24,733			—			—			24,733
Exercise of options	—			—		4			—			—			4
Tax withholding for restricted shares	—			—		(2,414		)	—			—			(2,414		)
Other	(1		)	—		—			—			—			(1		)
BALANCE, MARCH 31, 2019	$	45		$	22	$	8,878,133		$	(9,148,151	)	$	(224,499	)	$	(494,450	)
Net loss	—			—		—			(106,005		)	—			(106,005		)
Other comprehensive income	—			—		—			—			4,395			4,395
Compensation related to share-based awards	—			—		12,600			—			—			12,600
Tax withholding for restricted shares	—			—		(7,013		)	—			—			(7,013		)
Other	—			1		—			—			—			1
BALANCE, JUNE 30, 2019	$	45		$	23	$	8,883,720		$	(9,254,156	)	$	(220,104	)	$	(590,472	)
Net loss	—			—		—			(79,415		)	—			(79,415		)
Other comprehensive loss	—			—		—			—			(2,515		)	(2,515		)
Compensation related to share-based awards	—			—		11,576			—			—			11,576
Tax withholding for restricted shares	—			—		(650		)	—			—			(650		)
Other	(1		)	—		—			—			—			(1		)
BALANCE, SEPTEMBER 30, 2019	$	44		$	23	$	8,894,646		$	(9,333,571	)	$	(222,619	)	$	(661,477	)

__________


(1)	Refer to Note 2. Summary of Significant Accounting Policies for further description of ASC 842.

The following table presents a reconciliation of the beginning and ending balances in Total shareholders' equity (deficit) for the three and nine months ended September 30, 2018 (in thousands):



	Euro Deferred Shares			Ordinary Shares		Additional Paid-in Capital			Accumulated Deficit			Accumulated Other Comprehensive Loss			Total Shareholders' Equity (Deficit)
BALANCE, DECEMBER 31, 2017, PRIOR TO THE ADOPTION OF ASC 606 (1)	$	48		$	22	$	8,791,170		$	(8,096,539	)	$	(209,821	)	$	484,880
Effect of adopting ASC 606 (1)	—			—		—			3,076			—			3,076
BALANCE, JANUARY 1, 2018	$	48		$	22	$	8,791,170		$	(8,093,463	)	$	(209,821	)	$	487,956
Net loss	—			—		—			(505,489		)	—			(505,489		)
Other comprehensive loss	—			—		—			—			(5,797		)	(5,797		)
Compensation related to share-based awards	—			—		17,890			—			—			17,890
Tax withholding for restricted shares	—			—		(1,642		)	—			—			(1,642		)
Other	1			—		(12		)	—			—			(11		)
BALANCE, MARCH 31, 2018	$	49		$	22	$	8,807,406		$	(8,598,952	)	$	(215,618	)	$	(7,093	)
Net loss	—			—		—			(60,867		)	—			(60,867		)
Other comprehensive loss	—			—		—			—			(5,971		)	(5,971		)
Compensation related to share-based awards	—			—		12,096			—			—			12,096
Tax withholding for restricted shares	—			—		(234		)	—			—			(234		)
Other	(2		)	—		(6		)	—			—			(8		)
BALANCE, JUNE 30, 2018	$	47		$	22	$	8,819,262		$	(8,659,819	)	$	(221,589	)	$	(62,077	)
Net loss	—			—		—			(173,205		)	—			(173,205		)
Other comprehensive income	—			—		—			—			4,735			4,735
Compensation related to share-based awards	—			—		13,736			—			—			13,736
Exercise of options	—			—		473			—			—			473
Tax withholding for restricted shares	—			—		(3,206		)	—			—			(3,206		)
Other	(1		)	—		86			—			—			85
BALANCE, SEPTEMBER 30, 2018	$	46		$	22	$	8,830,351		$	(8,833,024	)	$	(216,854	)	$	(219,459	)

__________

(1)

Summary of Significant Accounting Policies - Narrative (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Jan. 01, 2019	Dec. 31, 2018	Jan. 01, 2018
Product Information [Line Items]
Operating lease ROU assets	$ 53,839		$ 0
Current operating lease liabilities	10,575		0
Noncurrent operating lease liabilities	$ 50,965		$ 0
Effect of adopting accounting principle in period of adoption		$ 4,646		$ (3,076)
Accumulated Deficit
Product Information [Line Items]
Effect of adopting accounting principle in period of adoption		4,646		$ (3,076)
ASC 842
Product Information [Line Items]
Operating lease ROU assets		59,400
Current operating lease liabilities		11,000
Noncurrent operating lease liabilities		57,300
ASC 842 \| Accumulated Deficit
Product Information [Line Items]
Effect of adopting accounting principle in period of adoption		$ 4,600

Discontinued Operations - Astora - Discontinued Operations (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Discontinued operations, net of tax	$ (37,984)	$ (27,134)	$ (51,898)	$ (43,273)
Discontinued operations, disposed of by means other than sale, abandonment \| Astora
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Litigation-related and other contingencies, net	30,000	19,000	30,400	19,000
Loss from discontinued operations before income taxes	(37,984)	(27,134)	(51,898)	(43,273)
Income tax benefit	0	0	0	0
Discontinued operations, net of tax	$ (37,984)	$ (27,134)	$ (51,898)	$ (43,273)

- Definition

Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.

+ References + Details

- Definition

Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.

+ References + Details

- Definition

Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.

+ References + Details

Discontinued Operations - Astora (Narrative) (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Restructuring Cost and Reserve [Line Items]
Loss from discontinued operations, net of tax	$ (37,984,000)	$ (27,134,000)	$ (51,898,000)	$ (43,273,000)
Discontinued operations, disposed of by means other than sale, abandonment \| Astora
Restructuring Cost and Reserve [Line Items]
Loss from discontinued operations, net of tax	$ (37,984,000)	$ (27,134,000)	(51,898,000)	(43,273,000)
Cash used in investing activities			0	0
Depreciation and amortization			$ 0	$ 0

- Definition

+ References + Details

Restructuring - 2017 Restructuring Initiatives (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended
	Sep. 30, 2019	Dec. 31, 2018	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Other restructuring charges
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	$ 4.4		$ 1.7	$ 6.3	$ 11.4
2017 US generic pharmaceuticals restructuring \| Generic Pharmaceuticals
Restructuring Cost and Reserve [Line Items]
Restructuring expenses			4.8		59.6
2017 US generic pharmaceuticals restructuring \| Accelerated depreciation
Restructuring Cost and Reserve [Line Items]
Restructuring expenses					35.2
2017 US generic pharmaceuticals restructuring \| Employee separation, retention, and other benefit related costs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses			2.1		9.8
2017 US generic pharmaceuticals restructuring \| Other restructuring charges
Restructuring Cost and Reserve [Line Items]
Restructuring expenses			$ 2.7		12.0
2017 US generic pharmaceuticals restructuring \| Property, plant and equipment impairment charges
Restructuring Cost and Reserve [Line Items]
Restructuring expenses					$ 2.6
Huntsville, Alabama manufacturing and distributing facility \| Disposal group, disposed of by sale, not discontinued operations \| 2017 US generic pharmaceuticals restructuring \| Facility closing
Restructuring Cost and Reserve [Line Items]
Proceeds from sale of property, plant and equipment		$ 23.1
Net gain on disposal		$ 12.5

Restructuring - Schedule of Restructuring Roll Forward (Details) - 2017 US generic pharmaceuticals restructuring $ in Thousands	9 Months Ended
	Sep. 30, 2019 USD ($)
Restructuring Reserve [Roll Forward]
Beginning liability balance	$ 4,287
Cash distributions	(4,287)
Ending liability balance	0
Employee separation, retention and other benefit-related costs
Restructuring Reserve [Roll Forward]
Beginning liability balance	4,239
Cash distributions	(4,239)
Ending liability balance	0
Other Restructuring Costs
Restructuring Reserve [Roll Forward]
Beginning liability balance	48
Cash distributions	(48)
Ending liability balance	$ 0

Restructuring - January 2018 Restructuring Initiative (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
January 2018 restructuring initiative
Restructuring Cost and Reserve [Line Items]
Remaining liability					$ 1.1
Employee separation, retention, and other benefit related costs \| January 2018 restructuring initiative
Restructuring Cost and Reserve [Line Items]
Restructuring expenses				$ 22.1
Other restructuring charges
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	$ 4.4	$ 1.7	$ 6.3	11.4
Other restructuring charges \| January 2018 restructuring initiative
Restructuring Cost and Reserve [Line Items]
Restructuring expenses				1.7
Generic Pharmaceuticals \| January 2018 restructuring initiative
Restructuring Cost and Reserve [Line Items]
Restructuring expenses				23.8
Operating segments \| Generic Pharmaceuticals \| January 2018 restructuring initiative
Restructuring Cost and Reserve [Line Items]
Restructuring expenses				10.8
Operating segments \| Sterile Injectables \| January 2018 restructuring initiative
Restructuring Cost and Reserve [Line Items]
Restructuring expenses				4.0
Operating segments \| International Pharmaceuticals \| January 2018 restructuring initiative
Restructuring Cost and Reserve [Line Items]
Restructuring expenses				3.1
Operating segments \| Branded Pharmaceuticals \| January 2018 restructuring initiative
Restructuring Cost and Reserve [Line Items]
Restructuring expenses				0.7
Corporate unallocated costs \| January 2018 restructuring initiative
Restructuring Cost and Reserve [Line Items]
Restructuring expenses				$ 5.2

Segment Results - Schedule of Reportable Segments Information (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2019 USD ($) Reportable_Business_Segments	Sep. 30, 2018 USD ($)
Segment Reporting Information [Line Items]
Number of reportable segments \| Reportable_Business_Segments			4
Total net revenues from external customers	$ 729,426	$ 745,466	$ 2,149,564	$ 2,160,689
Total segment adjusted income from continuing operations before income tax	330,362	351,152	983,553	1,068,267
Branded Pharmaceuticals
Segment Reporting Information [Line Items]
Total net revenues from external customers	217,313	220,100	629,851	632,972
Total segment adjusted income from continuing operations before income tax	91,444	84,891	253,417	262,454
Sterile Injectables
Segment Reporting Information [Line Items]
Total net revenues from external customers	263,635	237,150	777,963	670,847
Total segment adjusted income from continuing operations before income tax	197,974	170,329	566,345	513,082
Generic Pharmaceuticals
Segment Reporting Information [Line Items]
Total net revenues from external customers	218,012	257,969	654,322	748,445
Total segment adjusted income from continuing operations before income tax	29,433	82,555	128,738	247,137
International Pharmaceuticals
Segment Reporting Information [Line Items]
Total net revenues from external customers	30,466	30,247	87,428	108,425
Total segment adjusted income from continuing operations before income tax	$ 11,511	$ 13,377	$ 35,053	$ 45,594

Segment Results - Schedule of Reconciliations of Consolidated Adjusted Income (Loss) Before Income Tax (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Segment Reporting Information [Line Items]
Total consolidated loss from continuing operations before income tax	$ (24,070)	$ (143,068)	$ (120,363)	$ (671,559)
Interest expense, net	136,903	131,847	404,387	385,896
Amortization of intangible assets	131,900	161,300	417,949	471,700
Inventory step-up			0	261
Asset impairment charges	4,766	142,217	258,652	613,400
Acquisition-related costs	16,025	1,288	(26,983)	13,284
Gain on extinguishment of debt	0	0	(119,828)	0
Severance costs		2,100	2,200	32,700
Accelerated depreciation				35,200
Retention bonus
Segment Reporting Information [Line Items]
Restructuring expenses	6,700
Other restructuring charges
Segment Reporting Information [Line Items]
Restructuring expenses	4,400	1,700	6,300	11,400
Inventory write-offs
Segment Reporting Information [Line Items]
Restructuring expenses		200		2,800
Contract termination
Segment Reporting Information [Line Items]
Restructuring expenses	17,500		17,500
Premium associated with extending reporting period on expiring insurance program
Segment Reporting Information [Line Items]
Restructuring expenses	14,100		14,100
Segment reconciling items
Segment Reporting Information [Line Items]
Interest expense, net	136,903	131,847	404,387	385,896
Corporate unallocated costs	37,891	49,187	124,351	144,693
Amortization of intangible assets	131,932	161,275	417,949	471,662
Inventory step-up	0	71	0	261
Upfront and milestone payments to partners	1,672	4,731	4,055	43,027
Separation benefits and other cost reduction initiatives	11,023	4,001	15,172	82,141
Certain litigation-related and other contingencies, net	(14,414)	(1,750)	(4,093)	15,370
Asset impairment charges	4,766	142,217	258,652	613,400
Acquisition-related costs	16,025	1,288	(26,983)	13,284
Gain on extinguishment of debt	0	0	(119,828)	0
Foreign currency impact related to the remeasurement of intercompany debt instruments	(922)	1,528	2,874	(1,560)
Other, net	29,556	(175)	27,380	(28,348)
Operating segments
Segment Reporting Information [Line Items]
Total segment adjusted income from continuing operations before income tax	$ 330,362	$ 351,152	$ 983,553	$ 1,068,267

Segment Results - Schedule of Disaggregation of Revenues (Details) - USD ($)	3 Months Ended							9 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET	$ 729,426,000				$ 745,466,000			$ 2,149,564,000	$ 2,160,689,000
Product line revenue reporting threshold	25,000,000	$ 25,000,000	$ 25,000,000	$ 25,000,000	25,000,000	$ 25,000,000	$ 25,000,000
Branded Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET	217,313,000				220,100,000			629,851,000	632,972,000
Sterile Injectables
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET	263,635,000				237,150,000			777,963,000	670,847,000
Generic Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET	218,012,000				257,969,000			654,322,000	748,445,000
International Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET	$ 30,466,000				$ 30,247,000			$ 87,428,000	$ 108,425,000
International Pharmaceuticals \| Sales Revenue, Net \| Product Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	4.00%				4.00%			4.00%	5.00%
XIAFLEX® \| Branded Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET	$ 82,756,000				$ 64,214,000			$ 226,118,000	$ 184,855,000
SUPPRELIN® LA \| Branded Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET	20,772,000				20,408,000			66,542,000	60,948,000
Other Specialty \| Branded Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET	28,470,000				27,614,000			78,397,000	69,226,000
Total Specialty Products \| Branded Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET	131,998,000				112,236,000			371,057,000	315,029,000
PERCOCET® \| Branded Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET	28,561,000				30,730,000			88,199,000	93,539,000
TESTOPEL® \| Branded Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET	13,236,000				15,962,000			40,830,000	44,976,000
Other Established \| Branded Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET	43,518,000				61,172,000			129,765,000	179,428,000
Total Established Products \| Branded Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET	85,315,000				107,864,000			258,794,000	317,943,000
Vasostrict® \| Sterile Injectables
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET	129,691,000				112,333,000			384,854,000	332,387,000
ADRENALIN® \| Sterile Injectables
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET	40,311,000				35,460,000			133,468,000	101,858,000
APLISOL® \| Sterile Injectables
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET	28,085,000				15,992,000			55,996,000	49,064,000
Ertapenem for injection \| Sterile Injectables
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET	21,853,000				25,798,000			79,619,000	25,798,000
Other Sterile Injectables \| Sterile Injectables
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET	$ 43,695,000				$ 47,567,000			$ 124,026,000	$ 161,740,000
Colchicine Tablets \| Generic Pharmaceuticals \| Sales Revenue, Net \| Product Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	7.00%							6.00%

Fair Value Measurements - Restricted Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash and cash equivalents, current	$ 222,491	$ 305,368
Restricted cash and cash equivalents, noncurrent	22,357	22,356
Restricted cash and cash equivalents	244,848	327,724
Vaginal mesh cases
Restricted Cash and Cash Equivalents Items [Line Items]
Settlement funds	$ 221,645	$ 299,733

Fair Value Measurements (Narrative) (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2019 USD ($)	Sep. 30, 2018 USD ($)	Dec. 31, 2018 USD ($)
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Goodwill impairment charges	$ 0	$ 0	$ 151,108	$ 391,000
Money market funds \| Restricted cash and cash equivalents
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Settlement funds	$ 54,600		$ 54,600		$ 86,900
Discount rate \| Minimum
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Discount rate applied	0.095		0.095
Discount rate \| Maximum
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Discount rate applied	0.150		0.150
Discount rate \| Weighted average
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Discount rate applied	0.118		0.118

Fair Value Measurements - Financial Assets And Liabilities Measured At Fair Value On Recurring Basis (Details) - Fair value, measurements, recurring - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Acquisition-related contingent consideration—current
Liabilities:
Fair value of financial liabilities measured on recurring basis	$ 20,974	$ 36,514
Acquisition-related contingent consideration—noncurrent
Liabilities:
Fair value of financial liabilities measured on recurring basis	38,520	80,189
Money market funds
Assets:
Fair value of financial assets measured on recurring basis	748,441	137,215
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Acquisition-related contingent consideration—current
Liabilities:
Fair value of financial liabilities measured on recurring basis	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Acquisition-related contingent consideration—noncurrent
Liabilities:
Fair value of financial liabilities measured on recurring basis	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Money market funds
Assets:
Fair value of financial assets measured on recurring basis	748,441	137,215
Significant Other Observable Inputs (Level 2) \| Acquisition-related contingent consideration—current
Liabilities:
Fair value of financial liabilities measured on recurring basis	0	0
Significant Other Observable Inputs (Level 2) \| Acquisition-related contingent consideration—noncurrent
Liabilities:
Fair value of financial liabilities measured on recurring basis	0	0
Significant Other Observable Inputs (Level 2) \| Money market funds
Assets:
Fair value of financial assets measured on recurring basis	0	0
Significant Unobservable Inputs (Level 3) \| Acquisition-related contingent consideration—current
Liabilities:
Fair value of financial liabilities measured on recurring basis	20,974	36,514
Significant Unobservable Inputs (Level 3) \| Acquisition-related contingent consideration—noncurrent
Liabilities:
Fair value of financial liabilities measured on recurring basis	38,520	80,189
Significant Unobservable Inputs (Level 3) \| Money market funds
Assets:
Fair value of financial assets measured on recurring basis	$ 0	$ 0

Fair Value Measurements - Financial Liabilities Measured At Fair Value On Recurring Basis Using Significant Unobservable Inputs (Details) - Acquisition-related contingent consideration - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning of period	$ 52,930	$ 152,098	$ 116,703	$ 190,442
Amounts settled	(9,376)	(24,564)	(30,541)	(73,298)
Changes in fair value recorded in earnings	16,025	769	(26,983)	11,731
Effect of currency translation	(85)	167	315	(405)
Changes in Fair Value Recorded in Earnings			(26,983)
Amounts Settled and Other			(30,226)
End of period	59,494	$ 128,470	59,494	$ 128,470
Auxilium acquisition
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning of period			14,157
Changes in Fair Value Recorded in Earnings			1,086
Amounts Settled and Other			(388)
End of period	14,855		14,855
Lehigh Valley Technologies, Inc. acquisitions
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning of period			34,700
Changes in Fair Value Recorded in Earnings			10,566
Amounts Settled and Other			(14,466)
End of period	30,800		30,800
VOLTAREN® Gel acquisition
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning of period			56,240
Changes in Fair Value Recorded in Earnings			(37,395)
Amounts Settled and Other			(14,601)
End of period	4,244		4,244
Other
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning of period			11,606
Changes in Fair Value Recorded in Earnings			(1,240)
Amounts Settled and Other			(771)
End of period	$ 9,595		$ 9,595

- Fair Value Measurements (Schedule of Financial Assets Measured At Fair Value On A Nonrecurring Basis) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Assets:
Total expense for the year	$ (4,766)	$ (142,217)	$ (258,652)	$ (613,400)
Fair value, measurements, nonrecurring
Assets:
Total expense for the year			(107,544)
Fair value, measurements, nonrecurring \| Intangible assets
Assets:
Total expense for the year			(104,660)
Fair value, measurements, nonrecurring \| Certain property, plant and equipment
Assets:
Total expense for the year			(2,884)
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Fair value, measurements, nonrecurring
Assets:
Intangible assets, excluding goodwill	0		0
Certain property, plant and equipment	0		0
Total	0		0
Significant Other Observable Inputs (Level 2) \| Fair value, measurements, nonrecurring
Assets:
Intangible assets, excluding goodwill	0		0
Certain property, plant and equipment	0		0
Total	0		0
Significant Unobservable Inputs (Level 3) \| Fair value, measurements, nonrecurring
Assets:
Intangible assets, excluding goodwill	41,839		41,839
Certain property, plant and equipment	0		0
Total	$ 41,839		$ 41,839

Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw materials	$ 123,608	$ 122,825
Work-in-process	68,880	70,458
Finished goods	146,025	128,896
Total	338,513	322,179
Long-term inventory	23,700	8,100
Inventories not yet available for sale	$ 18,200	$ 12,500

Leases - Assets and Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
ROU assets:
Operating lease ROU assets	$ 53,839	$ 0
Finance lease ROU assets	59,104
Total ROU assets	112,943
Operating lease liabilities:
Current operating lease liabilities	10,575	0
Noncurrent operating lease liabilities	50,965	$ 0
Total operating lease liabilities	61,540
Finance lease liabilities:
Current finance lease liabilities	5,550
Noncurrent finance lease liabilities	32,768
Total finance lease liabilities	$ 38,318

Leases - Components of Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019
Leases [Abstract]
Operating lease cost	$ 3,510	$ 10,269
Finance lease cost:
Amortization of ROU assets	2,311	7,096
Interest on lease liabilities	271	1,256
Other lease costs and income:
Variable lease costs	2,318	7,185
Sublease income	(932)	(2,828)
Cost of revenues
Lessee, Lease, Description [Line Items]
Lease, cost	2,793	8,425
Selling, general and administrative expenses
Lessee, Lease, Description [Line Items]
Lease, cost	4,347	13,145
Research and development expenses
Lessee, Lease, Description [Line Items]
Lease, cost	$ 67	$ 152

Leases - Maturities of Operating and Finance Lease Liabilities (Details) $ in Thousands	Sep. 30, 2019 USD ($)
Operating Leases
2019, excluding amounts already paid	$ 3,740
2020	13,771
2021	13,996
2022	12,424
2023	10,012
Thereafter	20,549
Total future lease payments	74,492
Less: amount representing interest	12,952
Total operating lease liabilities	61,540
Finance Leases
2019, excluding amounts already paid	1,826
2020	7,447
2021	7,594
2022	7,744
2023	7,898
Thereafter	21,881
Total future lease payments	54,390
Less: amount representing interest	16,072
Total finance lease liabilities	$ 38,318

Leases - Future Minimum Lease Payment Obligations Under Operating and Capital Leases (Details) $ in Thousands	Sep. 30, 2019 USD ($)
Capital Leases
2019	$ 6,884
2020	6,819
2021	6,921
2022	7,072
2023	7,225
Thereafter	9,127
Total minimum lease payments	44,048
Less: Amount representing interest	4,084
Total present value of minimum payments	39,964
Less: Current portion of such obligations	5,845
Long-term capital lease obligations	34,119
Operating Leases
2019	15,800
2020	14,519
2021	12,883
2022	12,454
2023	9,945
Thereafter	20,573
Total minimum lease payments	$ 86,174

Leases - Weighted Average Term Lease and Discount Rates (Details)	Sep. 30, 2019
Weighted average remaining lease term (years), weighted based on lease liability balances:
Operating leases	6 years
Finance leases	9 years 8 months 12 days
Weighted average discount rate (percentages), weighted based on the remaining balance of lease payments:
Operating leases	5.80%
Finance leases	5.50%

Leases - Cash Flow and Supplemental Noncash Information (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2019 USD ($)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash payments for operating leases	$ 11,200
Operating cash payments for finance leases	1,535
Financing cash payments for finance leases	7,826
Lease liabilities arising from obtaining right-of-use assets:
Operating leases	623
Finance leases	$ 5,901

Goodwill and Other Intangibles - Schedule of Changes in the Carrying Amount of Goodwill (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Goodwill [Roll Forward]
Goodwill, beginning balance			$ 3,764,636
Effect of currency translation			1,794
Goodwill impairment charges	$ 0	$ 0	(151,108)	$ (391,000)
Goodwill, ending balance	3,615,322		3,615,322
Branded Pharmaceuticals
Goodwill [Roll Forward]
Goodwill, beginning balance			828,818
Effect of currency translation			0
Goodwill impairment charges			0
Goodwill, ending balance	828,818		828,818
Sterile Injectables
Goodwill [Roll Forward]
Goodwill, beginning balance			2,731,193
Effect of currency translation			0
Goodwill impairment charges			0
Goodwill, ending balance	2,731,193		2,731,193
Generic Pharmaceuticals
Goodwill [Roll Forward]
Goodwill, beginning balance			151,108
Effect of currency translation			0
Goodwill impairment charges			(151,108)
Goodwill, ending balance	0		0
International Pharmaceuticals
Goodwill [Roll Forward]
Goodwill, beginning balance			53,517
Effect of currency translation			1,794
Goodwill impairment charges			0
Goodwill, ending balance	$ 55,311		$ 55,311

Goodwill and Other Intangibles - Schedule of Other Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Indefinite-lived intangibles:
Beginning Balance			$ 93,900
Acquisitions			0
Impairments			0
Other			0
Effect of Currency Translation			0
Ending Balance	$ 93,900		93,900
Finite-lived intangibles:
Beginning Balance			6,645,826
Acquisitions			0
Impairments			(104,660)
Other			(2,196)
Effect of Currency Translation			7,443
Ending Balance	6,546,413		6,546,413
Total other intangibles
Beginning balance			6,739,726
Acquisitions			0
Impairments	(4,261)	$ (140,609)	(104,660)	$ (217,576)
Other			(2,196)
Effect of Currency Translation			7,443
Ending balance	6,640,313		6,640,313
Accumulated amortization:
Beginning Balance			(3,282,420)
Amortization	(131,900)	$ (161,300)	(417,949)	$ (471,700)
Impairments			0
Other			2,196
Effect of Currency Translation			(3,923)
Ending Balance	(3,702,096)		(3,702,096)
Net other intangibles	2,938,217		2,938,217		$ 3,457,306
Licenses
Finite-lived intangibles:
Beginning Balance			457,402
Acquisitions			0
Impairments			0
Other			0
Effect of Currency Translation			0
Ending Balance	457,402		457,402
Accumulated amortization:
Beginning Balance			(398,182)
Amortization			(9,726)
Impairments			0
Other			0
Effect of Currency Translation			0
Ending Balance	(407,908)		(407,908)
Tradenames
Finite-lived intangibles:
Beginning Balance			6,409
Acquisitions			0
Impairments			0
Other			0
Effect of Currency Translation			0
Ending Balance	6,409		6,409
Accumulated amortization:
Beginning Balance			(6,409)
Amortization			0
Impairments			0
Other			0
Effect of Currency Translation			0
Ending Balance	(6,409)		(6,409)
Developed technology
Finite-lived intangibles:
Beginning Balance			6,182,015
Acquisitions			0
Impairments			(104,660)
Other			(2,196)
Effect of Currency Translation			7,443
Ending Balance	6,082,602		6,082,602
Accumulated amortization:
Beginning Balance			(2,877,829)
Amortization			(408,223)
Impairments			0
Other			2,196
Effect of Currency Translation			(3,923)
Ending Balance	(3,287,779)		(3,287,779)
In-process research and development
Indefinite-lived intangibles:
Beginning Balance			93,900
Acquisitions			0
Impairments			0
Other			0
Effect of Currency Translation			0
Ending Balance	$ 93,900		$ 93,900
Weighted average
Accumulated amortization:
Intangible life (years)			11 years
Weighted average \| Licenses
Accumulated amortization:
Intangible life (years)			14 years
Weighted average \| Developed technology
Accumulated amortization:
Intangible life (years)			11 years

Goodwill and Other Intangibles - Schedule of Estimated Amortization of Intangibles (Details) $ in Thousands	Dec. 31, 2018 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2019	$ 543,795
2020	457,248
2021	415,637
2022	399,886
2023	$ 369,619

Goodwill and Other Intangibles - Impairments Narrative (Details)	3 Months Ended				9 Months Ended
	Sep. 30, 2019 USD ($)	Jun. 30, 2019 USD ($)	Sep. 30, 2018 USD ($)	Jun. 30, 2018 USD ($)	Sep. 30, 2019 USD ($)	Sep. 30, 2018 USD ($)
Goodwill [Line Items]
Goodwill impairment charges	$ 0		$ 0		$ 151,108,000	$ 391,000,000
Generic Pharmaceuticals
Goodwill [Line Items]
Goodwill impairment charges					$ 151,108,000
Generic Pharmaceuticals
Goodwill [Line Items]
Goodwill impairment charges	$ 65,100,000	$ 86,000,000.0		$ 391,000,000.0
Generic Pharmaceuticals \| Discount rate
Goodwill [Line Items]
Intangible assets and goodwill, measurement input	0.105	0.105			0.105
Former U.S generic pharmaceuticals
Goodwill [Line Items]
Goodwill impairment charges				0
Sterile injectables
Goodwill [Line Items]
Goodwill impairment charges				$ 0

Contract Assets and Liabilities - Contract Assets and Contract Liabilities from Contracts with Customers (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Contract with Customer, Asset and Liability [Abstract]
Contract assets, net	$ 4,283	$ 12,065
Contract assets, net - $ change	$ (7,782)
Contract assets, net - % change	(65.00%)
Contract liabilities, net	$ 6,864	19,217
Contract liabilities, net - $ change	$ (12,353)
Contract liabilities, net - % change	(64.00%)
Contract asset amounts classified as current	$ 4,300	9,300
Contract liability amounts classified as current	2,100	$ 1,700
Increase in contract liability	4,000
Reductions	14,900
Revenue recognized	$ 1,100

Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Accounts Payable and Accrued Liabilities, Current [Abstract]
Trade accounts payable	$ 110,074	$ 96,024
Returns and allowances	208,264	236,946
Rebates	140,184	144,860
Chargebacks	1,578	2,971
Accrued interest	101,085	130,182
Accrued payroll and related benefits	71,867	89,895
Accrued royalties and other distribution partner payables	111,347	122,028
Acquisition-related contingent consideration—current	20,974	36,514
Other	171,808	149,780
Total	$ 937,181	$ 1,009,200

Debt (Components of Total Indebtedness) (Details) - USD ($)	Sep. 30, 2019	Mar. 31, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Principal Amount	$ 8,479,215,000		$ 8,348,775,000
Carrying Amount	8,399,061,000		8,258,419,000
Less current portion, net	34,150,000		34,150,000
Principal amount of total long-term debt, less current portion, net	8,445,065,000		8,314,625,000
Carrying amount of total long-term debt, less current portion, net	8,364,911,000		8,224,269,000
Fair value of long term debt	$ 6,900,000,000		$ 7,200,000,000
Revolving Credit Facility
Debt Instrument [Line Items]
Effective interest rate (as percent)	4.63%
Principal Amount	$ 300,000,000		$ 0
Carrying Amount	$ 300,000,000		$ 0
7.25% Senior Notes due 2022
Debt Instrument [Line Items]
Effective interest rate (as percent)	7.25%		7.91%
Principal Amount	$ 8,294,000		$ 400,000,000
Carrying Amount	$ 8,294,000		$ 392,947,000
Interest rate (as percent)	7.25%	7.25%
5.75% Senior Notes due 2022
Debt Instrument [Line Items]
Effective interest rate (as percent)	5.75%		6.04%
Principal Amount	$ 182,479,000		$ 700,000,000
Carrying Amount	$ 182,479,000		$ 694,464,000
Interest rate (as percent)	5.75%	5.75%
5.375% Senior Notes due 2023
Debt Instrument [Line Items]
Effective interest rate (as percent)	5.62%		5.62%
Principal Amount	$ 210,440,000		$ 750,000,000
Carrying Amount	$ 208,912,000		$ 743,438,000
Interest rate (as percent)	5.375%
6.00% Senior Notes due 2023
Debt Instrument [Line Items]
Effective interest rate (as percent)	6.28%		6.28%
Principal Amount	$ 1,439,840,000		$ 1,635,000,000
Carrying Amount	$ 1,426,195,000		$ 1,616,817,000
Interest rate (as percent)	6.00%
5.875% Senior Secured Notes due 2024
Debt Instrument [Line Items]
Effective interest rate (as percent)	6.14%		6.14%
Principal Amount	$ 300,000,000		$ 300,000,000
Carrying Amount	$ 296,497,000		$ 296,062,000
Interest rate (as percent)	5.875%
6.00% Senior Notes due 2025
Debt Instrument [Line Items]
Effective interest rate (as percent)	6.27%		6.27%
Principal Amount	$ 1,200,000,000		$ 1,200,000,000
Carrying Amount	$ 1,185,135,000		$ 1,183,415,000
Interest rate (as percent)	6.00%
7.50% Senior Secured Notes due 2027
Debt Instrument [Line Items]
Effective interest rate (as percent)	7.71%
Principal Amount	$ 1,500,000,000	$ 1,500,000,000.0	$ 0
Carrying Amount	$ 1,481,758,000		$ 0
Interest rate (as percent)	7.50%	7.50%
Term Loan B Facility Due 2024
Debt Instrument [Line Items]
Effective interest rate (as percent)	6.59%		7.02%
Principal Amount	$ 3,338,162,000		$ 3,363,775,000
Carrying Amount	$ 3,309,791,000		$ 3,331,276,000

Debt (Credit Facility) (Narrative) (Details) - USD ($)	1 Months Ended	9 Months Ended
Debt (Credit Facility) (Narrative) (Details) - USD ($)	Jun. 30, 2019	Sep. 30, 2019	Sep. 30, 2018
Line of Credit Facility [Line Items]
Proceeds from lines of credit		$ 300,000,000	$ 0
Revolving Credit Facility
Line of Credit Facility [Line Items]
Proceeds from lines of credit	$ 300,000,000.0
Credit facility, remaining borrowing capacity		696,800,000
2017 credit agreement \| Revolving Credit Facility
Line of Credit Facility [Line Items]
Maximum borrowing capacity		$ 1,000,000,000.0

Debt (March 2019 Refinancing) (Details) - USD ($)	1 Months Ended	12 Months Ended
Debt (March 2019 Refinancing) (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2019
Debt Instrument [Line Items]
Principal amount		$ 8,348,775,000	$ 8,479,215,000
Repurchase principal amount of debt	$ 1,642,200,000
Repayments of debt	1,500,000,000.0
Gain on extinguishment of debt	(124,000,000.0)
Unamortized discount (premium) and debt issuance costs, net	$ 26,200,000
Before April 1, 2022
Debt Instrument [Line Items]
Redemption price (as percent)	100.00%
On or after April 1, 2022 beginning principal redemption
Debt Instrument [Line Items]
Redemption price (as percent)	105.625%
Until April 1, 2025 decrease in amount redeemed
Debt Instrument [Line Items]
Redemption price (as percent)	100.00%
Before April 1, 2022 principal redeemed, in part
Debt Instrument [Line Items]
Redemption percent of principal amount outstanding	35.00%
7.50% Senior Secured Notes due 2027
Debt Instrument [Line Items]
Principal amount	$ 1,500,000,000.0	0	$ 1,500,000,000
Interest rate (as percent)	7.50%		7.50%
Extinguishment of debt	$ (1,624,000,000.0)
Unamortized discount (premium) and debt issuance costs, net	$ 19,100,000
7.50% Senior Secured Notes due 2027 \| Before April 1, 2022 principal amount redeemed
Debt Instrument [Line Items]
Redemption price (as percent)	107.50%
7.25% Senior Notes due 2022
Debt Instrument [Line Items]
Principal amount		400,000,000	$ 8,294,000
Repurchase principal amount of debt	$ 389,900,000
Interest rate (as percent)	7.25%		7.25%
5.75% Senior Notes due 2022
Debt Instrument [Line Items]
Principal amount		700,000,000	$ 182,479,000
Interest rate (as percent)	5.75%		5.75%
5.375% Senior Notes due 2023
Debt Instrument [Line Items]
Principal amount		750,000,000	$ 210,440,000
Interest rate (as percent)			5.375%
6.00% Senior Notes due 2023
Debt Instrument [Line Items]
Principal amount		1,635,000,000	$ 1,439,840,000
Interest rate (as percent)			6.00%
Senior notes \| 5.75% Senior Notes due 2022
Debt Instrument [Line Items]
Repurchase principal amount of debt	$ 517,500,000
Senior notes \| 5.375% Senior Notes due 2023
Debt Instrument [Line Items]
Repurchase principal amount of debt	539,600,000
Senior notes \| 6.00% Senior Notes due 2023
Debt Instrument [Line Items]
Repurchase principal amount of debt	195,200,000
Senior notes \| Note repurchases
Debt Instrument [Line Items]
Unamortized discount (premium) and debt issuance costs, net	4,200,000
Revolving Credit Facility
Debt Instrument [Line Items]
Principal amount		0	$ 300,000,000
Extinguishment of debt		$ (22,800,000)
Unamortized discount (premium) and debt issuance costs, net	2,900,000
Revolving Credit Facility \| 2017 credit agreement
Debt Instrument [Line Items]
Commitments not extended	$ 76,000,000.0
Revolving Credit Facility \| 2017 credit agreement \| Minimum
Debt Instrument [Line Items]
Secured leverage ratio	3.50
Revolving Credit Facility \| 2017 credit agreement \| Maximum
Debt Instrument [Line Items]
Secured leverage ratio	4.50

Debt (Maturities on Long-Term Debt for Each of The Next Five Years) (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Maturities
2019		$ 34,150
2020		34,150
2021		34,150
2022		247,723
2023		1,684,430
Senior notes \| Senior notes maturing due 2022
Maturities
Long-term debt, maturity repayment deadline	91 days
Revolving Credit Facility
Maturities
Extinguishment of debt		$ 22,800

Commitments And Contingencies (Narrative) (Details) $ in Thousands	1 Months Ended																	3 Months Ended			9 Months Ended	12 Months Ended	21 Months Ended	22 Months Ended
	Sep. 30, 2019 USD ($)	Jul. 31, 2019 USD ($)	Jun. 30, 2019 USD ($)	May 31, 2019 class_action	Mar. 31, 2019 USD ($)	Jan. 31, 2019 d defendant	Dec. 31, 2018 USD ($) defendant	Nov. 30, 2018	Oct. 31, 2018	Sep. 30, 2018 USD ($)	Aug. 31, 2018 d	Jun. 30, 2018 theory	May 31, 2018	Mar. 31, 2018 d defendant	Feb. 28, 2018 defendant	Jan. 31, 2018 consultant d employee	Aug. 31, 2017 defendant	Sep. 30, 2019 USD ($)	Jun. 30, 2019 USD ($)	Mar. 31, 2019 USD ($)	Sep. 30, 2019 USD ($) case	Dec. 31, 2018 USD ($)	Sep. 30, 2019 USD ($)	Oct. 29, 2019 USD ($) case claim
Loss Contingencies [Line Items]
Reserve for loss contingencies	$ 684,100																	$ 684,100			$ 684,100		$ 684,100
Current portion of legal settlement accrual	674,943						$ 905,085											674,943			674,943	$ 905,085	674,943
Vaginal mesh cases
Loss Contingencies [Line Items]
Payments to plaintiffs and qualified settlement funds																							3,500,000
Settlement funds	221,645						$ 299,733											221,645			$ 221,645	299,733	$ 221,645
Testosterone cases \| Subsequent event
Loss Contingencies [Line Items]
Pending claims, number \| claim																								882
Opioid-related matters
Loss Contingencies [Line Items]
Number of putative class actions \| class_action				2
Settlement, amount awarded to other party	$ 10,000
Opioid-related matters \| Subsequent event
Loss Contingencies [Line Items]
Pending claims, number \| case																								2,500
Number of cases filed by states \| case																								18
Number of cases filed by hospitals, health systems, unions, welfare funds or other third-party \| case																								240
Number of cases alleging personal injury and/or wrongful death \| case																								140
Lidoderm cases
Loss Contingencies [Line Items]
Payments to plaintiffs and qualified settlement funds																				$ 30,000		$ 60,000
Settlement, amount awarded to other party										$ 100,000
Lidoderm cases \| Subsequent event
Loss Contingencies [Line Items]
Reserve for loss contingencies																								$ 10,000
Payments to plaintiffs and qualified settlement funds																								$ 90,000
AndroGel 1.62%
Loss Contingencies [Line Items]
Number of causation theories rejected \| theory												2
Number of causation theories \| theory												3
Public employees' retirement system of mississippi vs. endo international plc
Loss Contingencies [Line Items]
Settlement, amount awarded to other party			$ 50,000
Loss contingency accrual, period increase (decrease)																				50,000
Loss contingency, receivable					$ 50,000															$ 50,000
Bier v. endo international plc, et al.
Loss Contingencies [Line Items]
Settlement, amount awarded to other party		$ 82,500
Loss contingency accrual, period increase (decrease)																			$ 82,500
Loss contingency, receivable			$ 82,500																$ 82,500
Loss contingency, receivable, period increase (decrease)																		$ 20,000
Bier v. endo international plc, et al. \| Current and former directors and officers
Loss Contingencies [Line Items]
Number of additional defendants \| defendant																	4
Number of defendants \| defendant							4								20
AMS \| Vaginal mesh cases
Loss Contingencies [Line Items]
Loss contingency, claims settled, number \| case																					71,000
Par pharmaceutical, inc. \| VASOSTRICT related matters
Loss Contingencies [Line Items]
Number of additional defendants \| employee																4
Length of trial, number of days \| consultant																1
Number of defendants filing motion to dismiss the breach of contract claim \| defendant														7
Number of defendants filing motion to dismiss for lack of personal injury jurisdiction \| defendant														4
Number of defendants filing motion to dismiss breach of contract claim \| defendant														1
Number of defendants \| defendant						4
Stay of litigation, number of days \| d																60
Extension of temporary stay, number of days \| d											180			180
Number of days for plaintiff to file notice \| d						3
Lawsuit filing period	45 days		45 days		45 days			45 days	45 days				45 days
Stay of approval period, hatch-waxman act	30 months		30 months		30 months			30 months	30 months				30 months
VASOSTRICT and/or ADRENALIN \| Opioid-related matters
Loss Contingencies [Line Items]
Settlement, amount awarded to other party	$ 1,000

Commitments And Contingencies - Schedule of Loss Contingencies (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Qualified Settlement Funds
Cash contributions to Qualified Settlement Funds	$ 185,745	$ 216,770
Mesh Liability Accrual
Ending balance	684,100
Vaginal mesh cases
Qualified Settlement Funds
Beginning balance	299,733
Cash contributions to Qualified Settlement Funds	185,745
Cash distributions to settle disputes from Qualified Settlement Funds	(266,958)
Other	3,125
Ending balance	221,645
Mesh Liability Accrual
Other	3,125
Vaginal mesh cases \| Mesh product liability accrual
Qualified Settlement Funds
Additional charges	30,000
Other	3,256
Mesh Liability Accrual
Beginning balance	748,606
Cash distributions to settle disputes from Qualified Settlement Funds	(266,958)
Cash distributions to settle disputes	(13,334)
Other	3,256
Ending balance	$ 501,570

Shareholders' Deficit - Schedule of Changes in Shareholders' Equity (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Jan. 01, 2019	Dec. 31, 2018	Jan. 01, 2018
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shareholders' equity, beginning balance	$ (590,472)	$ (494,450)	$ (498,283)	$ (62,077)	$ (7,093)	$ 484,880	$ (498,283)	$ 484,880
Effect of adopting accounting principle in period of adoption									$ (4,646)		$ 3,076
Shareholders' equity, adjusted beginning balance									(502,929)		487,956
Net loss	(79,415)	(106,005)	(18,573)	(173,205)	(60,867)	(505,489)	(203,993)	(739,561)
Other comprehensive income (loss)	(2,515)	4,395	4,730	4,735	(5,971)	(5,797)	6,610	(7,033)
Compensation related to share-based awards	11,576	12,600	24,733	13,736	12,096	17,890
Exercise of options			4	473
Tax withholding for restricted shares	(650)	(7,013)	(2,414)	(3,206)	(234)	(1,642)
Other	(1)	1	(1)	85	(8)	(11)
Shareholders' equity, ending balance	(661,477)	(590,472)	(494,450)	(219,459)	(62,077)	(7,093)	(661,477)	(219,459)
Accumulated deficit	(9,333,571)						(9,333,571)			$ (9,124,932)
Euro Deferred Shares
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shareholders' equity, beginning balance	45	45	46	47	49	48	46	48
Shareholders' equity, adjusted beginning balance									46		48
Other	(1)		(1)	(1)	(2)	1
Shareholders' equity, ending balance	44	45	45	46	47	49	44	46
Ordinary Shares
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shareholders' equity, beginning balance	23	22	22	22	22	22	22	22
Shareholders' equity, adjusted beginning balance									22		22
Other	0	1
Shareholders' equity, ending balance	23	23	22	22	22	22	23	22
Additional Paid-in Capital
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shareholders' equity, beginning balance	8,883,720	8,878,133	8,855,810	8,819,262	8,807,406	8,791,170	8,855,810	8,791,170
Shareholders' equity, adjusted beginning balance									8,855,810		8,791,170
Compensation related to share-based awards	11,576	12,600	24,733	13,736	12,096	17,890	48,900	43,700
Exercise of options			4	473
Tax withholding for restricted shares	(650)	(7,013)	(2,414)	(3,206)	(234)	(1,642)
Other	0	0		86	(6)	(12)
Shareholders' equity, ending balance	8,894,646	8,883,720	8,878,133	8,830,351	8,819,262	8,807,406	8,894,646	8,830,351
Accumulated Deficit
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shareholders' equity, beginning balance	(9,254,156)	(9,148,151)	(9,124,932)	(8,659,819)	(8,598,952)	(8,096,539)	(9,124,932)	(8,096,539)
Effect of adopting accounting principle in period of adoption									(4,646)		3,076
Shareholders' equity, adjusted beginning balance									(9,129,578)		(8,093,463)
Net loss	(79,415)	(106,005)	(18,573)	(173,205)	(60,867)	(505,489)
Shareholders' equity, ending balance	(9,333,571)	(9,254,156)	(9,148,151)	(8,833,024)	(8,659,819)	(8,598,952)	(9,333,571)	(8,833,024)
Accumulated Other Comprehensive Loss
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shareholders' equity, beginning balance	(220,104)	(224,499)	(229,229)	(221,589)	(215,618)	(209,821)	(229,229)	(209,821)
Shareholders' equity, adjusted beginning balance									$ (229,229)		(209,821)
Other comprehensive income (loss)	(2,515)	4,395	4,730	4,735	(5,971)	(5,797)
Shareholders' equity, ending balance	$ (222,619)	$ (220,104)	$ (224,499)	$ (216,854)	$ (221,589)	$ (215,618)	$ (222,619)	$ (216,854)
Effect of adoption of ASC 606 \| ASC 606
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accumulated deficit											$ 3,100

Shareholders' (Deficit) Equity (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation related to share-based awards	$ 11,576	$ 12,600	$ 24,733	$ 13,736	$ 12,096	$ 17,890
Share-based compensation awards	61,600						$ 61,600
Additional Paid-in Capital
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation related to share-based awards	$ 11,576	$ 12,600	$ 24,733	$ 13,736	$ 12,096	$ 17,890	$ 48,900	$ 43,700
Nonvested Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Service period							1 year 1 month 6 days
Nonvested Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Service period							1 year 9 months 18 days

Other Expense (Income), Net (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Component of Operating Income [Abstract]
Net gain on sale of business and other assets (1)	$ (1,933)	$ (2,866)	$ (3,101)	$ (29,859)
Foreign currency loss (gain), net (2)	579	1,354	4,336	(734)
Net loss from our investments in the equity of other companies (3)	191	842	2,546	3,163
Other miscellaneous, net (4)	17,366	(837)	16,627	(5,786)
Other expense (income), net	16,203	$ (1,507)	20,408	$ (33,216)
Contract termination
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	$ 17,500		$ 17,500

Income Taxes (Schedule of Components of Continuing Operations Before Income Tax, Income Tax Expense, Effective Tax Rate (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Loss from continuing operations before income tax	$ (24,070)	$ (143,068)	$ (120,363)	$ (671,559)
Income tax expense	$ 17,361	$ 3,003	$ 31,732	$ 24,729
Effective tax rate	(72.10%)	(2.10%)	(26.40%)	(3.70%)

Net Loss Per Share (Reconciliation Of The Numerator And Denominator Of Basic And Diluted Net Loss Per Share) (Details) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018
Numerator:
Loss from continuing operations	$ (41,431)			$ (146,071)			$ (152,095)	$ (696,288)
Loss from discontinued operations, net of tax	(37,984)			(27,134)			(51,898)	(43,273)
NET LOSS	$ (79,415)	$ (106,005)	$ (18,573)	$ (173,205)	$ (60,867)	$ (505,489)	$ (203,993)	$ (739,561)
Denominator:
For basic per share data—weighted average shares (in shares)	226,598			224,132			225,804	223,829
Dilutive effect of ordinary share equivalents (in shares)	0			0			0	0
For diluted per share data—weighted average shares (in shares)	226,598			224,132			225,804	223,829

- Definition

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Other Comprehensive Income (Loss)	9 Months Ended
Other Comprehensive Income (Loss)	Sep. 30, 2019
Equity [Abstract]
OTHER COMPREHENSIVE INCOME (LOSS)	NOTE 14. OTHER COMPREHENSIVE INCOME (LOSS) There were no tax effects allocated to any component of Other comprehensive (loss) income for the three and nine months ended September 30, 2019 and 2018. Substantially all of the Company’s Accumulated other comprehensive loss balances at September 30, 2019 and December 31, 2018 consist of Foreign currency translation loss.

Leases - Narrative (Details)	9 Months Ended
Leases - Narrative (Details)	Sep. 30, 2019 renewal_options
Leases [Abstract]
Lessee, operating lease, number of renewal options	3
Lessee. operating lease, renewal term	60 months

Goodwill and Other Intangibles - Accumulated Impairment (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Goodwill [Line Items]
Accumulated impairment losses	$ 4,468,648	$ 4,303,767
Branded Pharmaceuticals
Goodwill [Line Items]
Accumulated impairment losses	855,810	855,810
Sterile Injectables
Goodwill [Line Items]
Accumulated impairment losses	0	0
Generic Pharmaceuticals
Goodwill [Line Items]
Accumulated impairment losses	3,142,657	2,991,549
International Pharmaceuticals
Goodwill [Line Items]
Accumulated impairment losses	$ 470,181	$ 456,408

Contract Assets and Liabilities - Narrative (Details) $ in Millions	9 Months Ended
	Sep. 30, 2019 USD ($)
Contract with Customer, Asset and Liability [Abstract]
Performance obligation satisfied in previous period	$ 6.7